RiceBran Technologies (RIBT) 10-Q 9 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 03, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	RiceBran Technologies
Entity Central Index Key	1,063,537
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		16,884,017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Condensed Consolidated Statements of Operations (Unaudited) [Abstract]
Revenues	$ 3,445	$ 3,249	$ 10,206	$ 9,748
Cost of goods sold	2,305	2,434	7,081	7,199
Gross profit	1,140	815	3,125	2,549
Selling, general and administrative expenses	2,495	3,140	7,428	9,428
Loss from operations	(1,355)	(2,325)	(4,303)	(6,879)
Other (expense) income:
Interest expense	(86)	(352)	(1,616)	(1,484)
Change in fair value of derivative warrant liabilities	(313)	1,166	808	314
Loss on extinguishment of debt	(6,610)	0	(8,290)	0
Loss on conversion of preferred stock	(85)	0	(85)	0
Gain on resolution of Irgovel purchase litigation	0	0	0	1,598
Other income	157	132	194	132
Other expense	(28)	0	(128)	0
Total other (expense) income	(6,965)	946	(9,117)	560
Loss before income taxes	(8,320)	(1,379)	(13,420)	(6,319)
Income tax benefit	4,121	437	5,033	1,344
Loss from continuing operations	(4,199)	(942)	(8,387)	(4,975)
Income (loss) from discontinued operations, net of tax	6,706	(608)	6,823	(4,829)
Net income (loss)	2,507	(1,550)	(1,564)	(9,804)
Less - Net loss attributable to noncontrolling interest in discontinued operations	(792)	(470)	(1,359)	(2,416)
Net income (loss) attributable to RiceBran Technologies shareholders	3,299	(1,080)	(205)	(7,388)
Less - Dividends on preferred stock, beneficial conversion feature	0	0	778	551
Net income (loss) attributable to RiceBran Technologies common shareholders	$ 3,299	$ (1,080)	$ (983)	$ (7,939)
Basic earnings (loss) per common share:
Continuing operations (in dollars per share)	$ (0.38)	$ (0.10)	$ (0.86)	$ (0.60)
Discontinued operations (in dollars per share)	0.68	(0.01)	0.77	(0.26)
Basic earnings (loss) per common share - RiceBran Technologies (in dollars per share)	0.30	(0.11)	(0.09)	(0.86)
Diluted earnings (loss) per common share:
Continuing operations (in dollars per share)	(0.38)	(0.10)	(0.86)	(0.60)
Discontinued operations (in dollars per share)	0.68	(0.01)	0.77	(0.26)
Diluted earnings (loss) per common share - RiceBran Technologies (in dollars per share)	$ 0.30	$ (0.11)	$ (0.09)	$ (0.86)
Weighted average number of shares outstanding:
Basic (in shares)	11,129,781	9,397,255	10,644,372	9,281,942
Diluted (in shares)	11,129,781	9,397,255	10,644,372	9,281,942

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) [Abstract]
Net income (loss)	$ 2,507	$ (1,550)	$ (1,564)	$ (9,804)
Other comprehensive income - foreign currency translation, net of tax	(31)	(165)	131	694
Comprehensive income (loss), net of tax	2,476	(1,715)	(1,433)	(9,110)
Less - Comprehensive loss attributable to noncontrolling interest, net of tax	(803)	(330)	(1,321)	(1,998)
Total comprehensive income (loss) attributable to RiceBran Technologies shareholders	$ 3,279	$ (1,385)	$ (112)	$ (7,112)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 8,187	$ 342
Restricted cash	775	0
Accounts receivable, net of allowance for doubtful accounts of $8 and $12	1,384	1,094
Inventories	758	933
Deposits and other current assets	359	824
Current assets held for sale	2,398	4,335
Total current assets	13,861	7,528
Property and equipment, net	7,123	7,025
Intangible assets, net	135	242
Noncurrent assets held for sale	11,785	14,050
Total assets	32,904	28,845
Current liabilities:
Accounts payable	261	714
Accrued salary, wages and benefits	605	496
Accrued expenses	309	1,288
Income taxes payable	268	0
Current maturities of long-term debt	19	3,063
Current liabilities held for sale	18,239	15,801
Total current liabilities	19,701	21,362
Long-term debt, less current portion	13	5,964
Derivative warrant liabilities	769	1,527
Deferred tax liability	29	29
Noncurrent liabilities held for sale	0	44
Total liabilities	20,512	28,926
Commitments and contingencies
Temporary equity
Total temporary equity	0	551
Equity (deficit) attributable to RiceBran Technologies shareholders:
Common stock, no par value, 50,000,000 shares authorized, 16,551,350 and 10,790,351 shares issued and outstanding	278,079	264,232
Accumulated deficit	(260,802)	(259,819)
Accumulated deficit attributable to noncontrolling interest in discontinued operation	(1,370)	(699)
Accumulated other comprehensive loss	(4,253)	(4,346)
Total equity (deficit) attributable to RiceBran Technologies shareholders	12,392	(632)
Total liabilities, temporary equity and equity (deficit)	32,904	28,845
Series F Convertible Preferred Stock [Member]
Temporary equity
Preferred stock, Series F, convertible, 20,000,000 shares authorized, 3,000 convertible shares issued and outstanding	0	551
Equity (deficit) attributable to RiceBran Technologies shareholders:
Preferred stock	92	0
Series G Convertible Preferred Stock [Member]
Equity (deficit) attributable to RiceBran Technologies shareholders:
Preferred stock	$ 646	$ 0

Condensed Consolidated Balance5

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Accounts receivable, allowance for doubtful accounts	$ 8	$ 12
Equity (deficit) attributable to RiceBran Technologies shareholders:
Preferred stock, shares authorized (in shares)	20,000,000
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	16,551,350	10,790,351
Common stock, shares outstanding (in shares)	16,551,350	10,790,351
Series F Convertible Preferred Stock [Member]
Temporary equity
Preferred stock, shares authorized (in shares)		20,000,000
Convertible preferred stock, shares issued (in shares)		3,000
Convertible preferred stock, shares outstanding (in shares)		3,000
Equity (deficit) attributable to RiceBran Technologies shareholders:
Preferred stock, shares authorized (in shares)	3,000
Convertible preferred stock, shares issued (in shares)	499
Convertible preferred stock, shares outstanding (in shares)	499
Series G Convertible Preferred Stock [Member]
Equity (deficit) attributable to RiceBran Technologies shareholders:
Preferred stock, shares authorized (in shares)	3,000
Convertible preferred stock, shares issued (in shares)	1,300
Convertible preferred stock, shares outstanding (in shares)	1,300

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flow from operating activities:
Net income (loss)	$ (1,564)	$ (9,804)
Income (loss) from discontinued operations	6,823	(4,829)
Loss from continuing operations	(8,387)	(4,975)
Net cash used in operating activities of continuing operations:
Depreciation and amortization	571	694
Stock and share-based compensation	904	841
Change in fair value of derivative warrant and conversion liabilities	(808)	(314)
Loss on extinguishment of debt	8,290	0
Gain on resolution of Irgovel purchase litigation	0	(1,598)
Interest accreted	1,000	497
Deferred taxes	(5,033)	(1,344)
Other	55	0
Changes in operating assets and liabilities:
Accounts receivable	(290)	(182)
Inventories	213	576
Accounts payable and accrued expenses	(1,310)	3
Other	465	53
Net cash used in operating activities of continuing operations	(4,330)	(5,749)
Net cash provided by operating activities of discontinued operations	1,513	3,714
Net cash used in operating activities	(2,817)	(2,035)
Cash flows from investing activities:
Purchases of property	(596)	(208)
Net cash used in investing activities of continuing operations	(596)	(208)
Net cash provided by (used in) investing activities of discontinued operations	16,604	(252)
Net cash provided by (used in) investing activities	16,008	(460)
Cash flows from financing activities:
Payments of debt	(19,728)	(24,124)
Proceeds from issuance of debt, net of issuance costs	3,779	23,752
Proceeds from issuance of debt and warrants, net of issuance costs	5,518	300
Proceeds from issuance of preferred stock and warrants, net of issuance costs	1,747	2,554
Net proceeds from issuance of common stock	2,778	0
Other	(23)	(9)
Net cash provided by (used in) financing activities of continuing operations	(5,929)	2,473
Net cash provided by (used in) financing activities of discontinued operations	1,232	(551)
Net cash provided by (used in) financing activities	(4,697)	1,922
Effect of exchange rate changes on cash and cash equivalents of discontinued operations	126	(182)
Net change in cash and cash equivalents and restricted cash	8,620	(755)
Cash and cash equivalents and restricted cash, beginning of period
Cash and cash equivalents	342	966
Restricted cash	0	1,921
Cash and cash equivalents and restricted cash, beginning of period	342	2,887
Cash and cash equivalents and restricted cash, end of period
Cash and cash equivalents	8,187	2,132
Restricted cash	775	0
Cash and cash equivalents and restricted cash, end of period	8,962	2,132
Supplemental disclosures, continuing operations:
Cash paid for interest of continuing operations	729	780
Cash paid for income taxes of continuing operations	$ 0	$ 20

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2017
BASIS OF PRESENTATION [Abstract]
BASIS OF PRESENTATION	NOTE 1. BASIS OF PRESENTATION In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q; therefore, as permitted under these rules, certain footnotes and other financial information included in complete financial statements were condensed or omitted. The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented. These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2016. The report of our independent registered public accounting firm that accompanies the audited consolidated financial statements for the year ended December 31, 2016, included in that Annual Report on Form 10-K, contains a going concern explanatory paragraph in which our independent registered public accounting firm expressed substantial doubt about our ability to continue as a going concern. The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared assuming we will continue as a going concern based on the realization of assets and the satisfaction of liabilities in the normal course of business.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	9 Months Ended
	Sep. 30, 2017
DISCONTINUED OPERATIONS [Abstract]
DISCONTINUED OPERATIONS	NOTE 2. DISCONTINUED OPERATIONS Healthy Natural (HN) Discontinued Operations The Company continuously assesses the composition of our business portfolio to ensure it is aligned with our strategic objectives and positioned to maximize growth and return to our shareholders. In the second quarter of 2017, we began exploring strategic options for our wholly-owned subsidiary, Healthy Natural, Inc. (HN). On a preliminary basis, we estimate the proceeds, net of expenses, at $16.7 million, the net carrying value of HN as of the date of sale at $3.5 million and the third quarter 2017 gain on sale as $8.8 million, net of a $4.3 million income tax provision. We currently expect to obtain the amounts held in escrow without adjustment. The following table summarizes the estimated carrying amount of HN as of the July 2017 sale (in thousands). Accounts receivable, net $ 871 Inventories 1,987 Other current assets 47 Property and equipment 871 Intangible 791 Other 24 Assets 4,591 Accounts payable 759 Accrued expenses 290 Liabilities 1,049 Net assets sold $ 3,542 We determined that the disposal met the criteria for presentation as discontinued operations in the second quarter of 2017. Accordingly, HN results are presented as discontinued operations in our consolidated statements of operations and are excluded from continuing operations for all periods presented. In addition, the HN assets and liabilities are classified as held for sale in our consolidated balance sheets for all periods presented. The operations of HN are included in our results though the July 14, 2017 date of sale. All following tables represent activity up to the date of the sale. The following table summarizes the major line items included in the income (loss) from discontinued operations for the divestiture of HN (in thousands). Three Months Ended Nine Months Ended 2017 2016 2017 2016 Revenues $ 421 $ 5,010 $ 9,902 $ 15,044 Cost of goods sold (293 ) (3,330 ) (6,651 ) (9,991 ) Selling, general and administrative expenses (19 ) (396 ) (462 ) (1,100 ) Income from operations, before income taxes 109 1,284 2,789 3,953 Income tax expense (36 ) (437 ) (948 ) (1,344 ) Income from operations, net of tax 73 847 1,841 2,609 Gain on sale, net of $4.3 million income tax expense 8,845 - 8,845 - Income from discontinued operations, net of tax $ 8,918 $ 847 $ 10,686 $ 2,609 We expect to have sufficient net operating losses to offset the taxable gain related to the sale of HN and HN’s taxable operating income in 2017. Alternative minimum tax may be due on the sale of HN based on the calculation of alternative minimum taxable income, which allows taxable income to only be offset by 90% by net operating loss carryforwards; thereby leaving residual taxable income of 10%, subject to a rate of 20%. We currently estimate $0.3 million to be payable under the alternative minimum tax but we will continue to evaluate the use of additional current year operating losses to offset the taxable income. The following table summarizes the carrying amounts of major classes of HN assets and liabilities classified as held for sale as of December 31, 2016 (in thousands). December 31, Accounts receivable, net $ 592 Inventories 1,915 Other current assets held for sale 23 Property and equipment 1,019 Intangible 791 Other noncurrent assets 24 Total assets held for sale $ 4,364 Accounts payable $ 443 Accrued expenses 382 Long term liabilities 44 Total liabilities held for sale $ 869 The following table summarizes the major line items included in cash flows from discontinued operations of HN for the nine months ended September 30, 2017 and 2016 (in thousands). Nine Months Ended 2017 2016 Net cash provided by operating activities $ 2,803 $ 3,701 Net cash provided by (used in) investing activities 16,719 (73 ) Net cash used in financing activities (48 ) - Net cash provided to continuing operations $ (19,474 ) $ (3,628 ) In 2017, net cash provided by investing activities in the table above is presented in our consolidated statements of cash flows in net cash provided by (used in) investing activities of discontinued operations and includes the $16.7 million net proceeds from the sale of HN. The following table summarizes other data for HN (in thousands). Three Months Ended Nine Months Ended 2017 2016 2017 2016 Depreciation included in cost of goods sold $ 7 $ 42 $ 96 $ 130 Depreciation included in selling, general and administrative expenses 4 20 49 58 Amortization included in selling, gneral and administrative expenses - 204 - 659 Capital expenditures 3 22 18 95 Nutra SA Discontinued Operations We hold a variable interest in our equity interest in Nutra SA. Nutra SA’s only operating subsidiary is Industria Riograndens De Oleos Vegetais Ltda. (Irgovel), located in Pelotas, Brazil. We are the primary beneficiary of Nutra SA, and as such, Nutra SA’s assets, liabilities and results of operations are included in the condensed consolidated financial statements. In the second quarter of 2017, we determined that our plans to divest our investment in Nutra SA met the criteria for presentation as discontinued operations. Accordingly, the Nutra SA operating results are presented as discontinued operations in our condensed consolidated statements of operations and are excluded from continuing operations for all periods presented. In addition, Nutra SA consolidated assets and liabilities are classified as held for sale in our consolidated balance sheets for all periods presented. Other equity holders’ (Investors) interests in Nutra SA are reflected in net loss attributable to noncontrolling interest in discontinued operations in the condensed consolidated statements of operations and accumulated deficit attributable to noncontrolling interest in discontinued operations in the condensed consolidated balance sheets. The following table summarizes the major line items included in income (loss) from discontinued operations for Nutra SA in the three and nine months ended September 30, 2017 and 2016 (in thousands). Three Months Ended Nine Months Ended 2017 2016 2017 2016 Revenues $ 3,226 $ 563 $ 9,589 $ 4,627 Cost of goods sold (3,539 ) (1,154 ) (9,814 ) (6,103 ) Selling, general and administrative expenses (1,541 ) (509 ) (2,572 ) (1,891 ) Goodwill impairment - - - (3,024 ) Other expense (358 ) (355 ) (1,066 ) (1,047 ) Loss from discontinued operations, before income taxes (2,212 ) (1,455 ) (3,863 ) (7,438 ) Income taxes - - - - Loss from discontinued operations, net of tax $ (2,212 ) $ (1,455 ) $ (3,863 ) $ (7,438 ) The following table summarizes the carrying amounts of major classes of Nutra SA assets and liabilities classified as held for sale (in thousands). September 30, December 31, Cash and cash equivalents $ 54 $ 109 Accounts receivable, net (restricted) 781 398 Inventories 1,237 925 Other current asssets 326 373 Property and equipment, net (restricted $2,662 and $2,599) 10,464 10,889 Other noncurrent assets 1,321 1,327 Total assets held for sale $ 14,183 $ 14,021 Accounts payable $ 2,338 $ 2,553 Accrued expenses 8,274 5,607 Current maturities of long-term debt (nonrecourse) 7,627 6,816 Total liabilities held for sale $ 18,239 $ 14,976 Cash provided by Nutra SA operations are generally unavailable for distribution to our Corporate and USA segment pursuant to the terms of the LLC Agreement. Therefore Nutra SA’s consolidated cash is classified as held for sale in our consolidated balance sheets. Nutra SA’s debt is secured by Irgovel’s accounts receivable and property. The non-Brazilian entities within the consolidated ownership group do not guarantee any of Nutra SA’s debt. The following table summarizes the major line items included in cash flows from Nutra SA discontinued operations for the nine months ended September 30, 2017 and 2016 (in thousands). Nine Months Ended 2017 2016 Net cash used in operating activities $ (1,345 ) $ (9 ) Net cash used in investing activities (115 ) (157 ) Net cash provided (used) by financing activities 1,280 (551 ) Net cash provided by continuing operations - 863 Effect of exchange rate changes 125 (183 ) Net change in cash and cash equivalents (55 ) (37 ) Cash and cash equivalents, beginning of period 109 104 Cash and cash equivalents, end of period $ 54 $ 67 The following table summarizes other data for Nutra SA (in thousands). Three Months Ended Nine Months Ended 2017 2016 2017 2016 Depreciation included in cost of goods sold $ 274 $ 246 $ 792 $ 672 Depreciation included in selling, general and administrative expenses 15 16 46 42 Capital expenditures 22 1 115 157 Nutra SA’s debt consists of the following (in thousands): September 30 December 31, Capital expansion loans $ 2,635 $ 2,454 Working capital lines of credit 1,081 401 Advances on customer export orders 785 1,113 Special tax programs 3,014 2,767 Other 112 81 $ 7,627 $ 6,816 As of September 30, 2017, Irgovel had approximately $0.4 million (USD) of debt installment payments in arrears. The banks have not called these loans in default, and management continues to work with the lenders to renegotiate payment terms, however, all Nutra SA debt has been classified as current liabilities held for sale in the accompanying condensed consolidated balance sheet as of September 30, 2017. As of September 30, 2017, Irgovel had approximately $9.3 million of tax and tax related payments in arrears. Approximately $0.2 million of the tax payments in arrears is related to certain unpaid employer tax from April 2017 through September 2017. All tax and tax related payments in arrears, other than the certain unpaid employer tax, can be included in a new Brazil tax amnesty program, but to qualify to do so, an entrance fee of approximately $0.4 million must be paid prior to November 15, 2017. At this time it is not certain Irgovel will qualify for the new Brazil tax amnesty. If Irgovel is unable to qualify for the new Brazil tax amnesty, Irgovel will likely petition the tax authorities seeking a favorable payment plan but it is likely the installment payments will not exceed 60 monthly payments. All Nutra SA debt is denominated in the Brazilian Real (R$), except advances on customer export orders which are denominated in U.S. Dollars. The fair value of Nutra SA debt (Level 3 measurement) approximates the carrying value of that debt based on the current market rates for similar debt with similar maturities. Cash provided by operations in our Brazil segment is generally unavailable for distribution to our Corporate and USA segment pursuant to the terms of the limited liability company agreement of Nutra SA (LLC Agreement). A summary of changes in redeemable noncontrolling interest in Nutra SA, reflected as accumulated deficit attributable to noncontrolling interest in discontinued operations, in the accompanying condensed consolidated balance sheets, for the three and nine months ended September 30, 2017 and 2016 (in thousands) follows. Three Months Ended Nine Months Ended 2017 2016 2017 2016 Redeemable noncontrolling interest in Nutra SA, beginning of period $ (567 ) $ (1,599 ) $ (699 ) $ 69 Investors' interest in net loss of Nutra SA (792 ) (470 ) (1,359 ) (2,416 ) Investors' interest in other comprehensive loss of Nutra SA (11 ) (60 ) 38 218 Investors purchase of additional membership interest - 200 650 200 Redeemable noncontrolling interest in Nutra SA, end of period $ (1,370 ) $ (1,929 ) $ (1,370 ) $ (1,929 ) Investors' average interest in Nutra SA during the period 35.8 % 32.5 % 35.5 % 32.2 % Investors' interest in Nutra SA at the end of the period 35.8 % 32.7 % 35.8 % 32.7 % The Investors have drag along rights which provide the Investors the ability to force a sale of Nutra SA assets after January 1, 2018. The right terminates upon the occurrence of certain events (a $50 million Nutra SA initial public offering or a change of control, as defined in the LLC Agreement). We may elect to exercise a right of first refusal to purchase the Investors’ interest instead of proceeding to a sale. We have assessed the likelihood of the Investors exercising these rights as less than probable at September 30, 2017. We will continue to evaluate the probability of the Investors exercising their drag along rights each reporting period. We will begin to accrete the redeemable noncontrolling interest to fair value if and when it is probable the Investors will exercise these rights. As the result of an amendment effective March 31, 2017, the Investors right to elect to exchange units in Nutra SA for our common stock terminated. In exchange for the termination of this right, we paid the Investors $0.1 million. Under the LLC Agreement, the business of Nutra SA is to be conducted by the manager, currently our EVP of Special Projects, subject to the oversight of the management committee. The management committee is comprised of three of our representatives and two of Investors’ representatives. Upon an event of default or a qualifying event, we will no longer control the management committee and the management committee will include three Investors’ representatives and two of our representatives. In addition, following an event of default or a qualifying event, a majority of the members of the management committee may replace the manager of Nutra SA. As of September 30, 2017, there have been no unwaived events of default. Events of default, as defined in the Membership Interest Purchase Agreement (MIPA) and the October 2013 amendment of investment agreements, are the failure of Irgovel to meet minimum annual processing targets or to achieve EBITDA on a local currency basis of at least R$4.0 million annually. As of September 30, 2017, there have been no qualifying events. The LLC Agreement defines a qualifying event as the bankruptcy of RiceBran Technologies or Nutra SA. In evaluating whether we are the primary beneficiary of Nutra SA, we considered the matters which could be put to a vote of the members. Until there is an event of default or a qualifying event, the Investors’ rights and abilities, individually or in the aggregate, do not allow them to substantively participate in the operations of Nutra SA. The Investors do not currently have the ability to dissolve Nutra SA or otherwise force the sale of all its assets. However, the Investors do have drag along rights in the future. We will continue to evaluate whether we are the primary beneficiary of Nutra SA each reporting period.

LIQUIDITY, GOING CONCERN AND MA

LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLAN	9 Months Ended
	Sep. 30, 2017
LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLAN [Abstract]
LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLAN	NOTE 3. LIQUIDITY, GOING CONCERN AND MANAGEMENT’S PLAN Our cash position has improved since December 31, 2016, as a result of a debt and equity raise in February 2017, the sale of HN in July 2017 and an equity raise in September 2017. However, our continued operations continued to experience losses and negative cash flows from operations which raises substantial doubt about our ability to continue as a going concern for a period of one year from the issue date of these financial statements. In February 2017, as discussed further in Note 8, we received net proceeds of $7.2 million from the sale and issuance of preferred stock, senior debentures and related warrants. The net proceeds were used in part to pay in full amounts owing our previous senior lender ($3.8 million) and to pay principal and accrued interest on our subordinated notes ($0.5 million). In July 2017, as discussed further in Note 2, we received cash proceeds, net of expenses, of $16.7 million from the sale of HN a portion of which was used to pay off our senior debentures ($6.6 million) and subordinated notes ($6.0 million). In September 2017, as discussed further in Note 8, we received net proceeds of $2.7 million from the sale and issuance of common stock. We continue to believe that we will be able to obtain additional funds to operate our business, should it be necessary; however, there can be no assurances that our efforts will prove successful. The accompanying financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. Beginning in the second quarter of 2016 and through the third quarter of 2017, Irgovel experienced severe cash shortages resulting in an increase in accrued expenses and payroll related tax obligations. In 2016, our minority partners (the Investors) contributed $1.7 million to Nutra SA and an additional $0.7 million through September 30, 2017. In 2016, we invested $1.1 million in Nutra SA. Our board has determined we will not contribute any additional funds to Nutra SA.

RECENT ACCOUNTING GUIDANCE

RECENT ACCOUNTING GUIDANCE	9 Months Ended
	Sep. 30, 2017
RECENT ACCOUNTING GUIDANCE [Abstract]
RECENT ACCOUNTING GUIDANCE	NOTE 4. RECENT ACCOUNTING GUIDANCE Recent accounting standards not yet adopted In May 2014, the Financial Accounting Standards Board (FASB) issued guidance on revenue from contracts with customers to clarify the principles for recognizing revenue and develop a common revenue standard for GAAP and International Financial Reporting Standards. Under the new guidance, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services, applying the following steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. An entity may choose to adopt the new standard either retrospectively or through a cumulative effect adjustment as of the start of the first period for which it applies the new standard. The guidance is effective for our annual and interim periods beginning in 2018, however, early adoption is permitted. We have begun to evaluate the impact that adoption of this guidance will have on our consolidated financial statements but have not completed the evaluation and implementation process. We expect to transition through a cumulative effect adjustment as of January 1, 2018. Under the modified retrospective method adoption will have no impact on reported results of operations, financial position and cash flows of discontinued operations, with respect to HN, because we no longer reflect HN operations in our consolidated results after the sale of HN in July 2017. Similarly, if we dispose of Nutra SA, before December 31, 2017, we expect adoption will have no impact on reported results of operations, financial position and cash flows of discontinued operations, with respect to Nutra SA as well. In February 2016, the FASB issued guidance which changes the accounting for leases. Under prior GAAP, the recognition, measurement and presentation of expenses and cash flows arising from a lease for us as a lessee depend primarily on the lease’s classification as a finance or operating lease. For both types of leases, lessees will recognize a right-of-use asset and a lease liability. For capital or finance leases, lessees will recognize amortization of the right-of-use asset separately from interest expense on the lease liability. The guidance is effective for our annual and interim periods beginning in 2019 and must be adopted on a modified retrospective approach. Early adoption is allowed. We have not yet determined the impact that the new guidance will have on our results of operations, financial position and cash flows and have not yet determined if we will early adopt the standard. Recently adopted accounting standards In May 2017, the FASB issued guidance that clarifies the scope of asset derecognition guidance and accounting for partial sales of nonfinancial assets. We adopted the standard early, as of January 1, 2017, with no effect on our financial position or results of operations. In February 2017, the FASB issued guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. We adopted the standard early, as of January 1, 2017, with no effect on our financial position or results of operations. In January 2017, the FASB issued a new goodwill impairment standard that simplifies the goodwill impairment testing methodology. The new standard eliminates Step 2 of the goodwill impairment test, in which an entity determines the fair value at the test date of its assets and liabilities using the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. We adopted the standard early, as of January 1, 2017, with no effect on our financial position or results of operations. In November 2016, the FASB issued guidance that requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. We were required to adopt the guidance for our annual and interim periods beginning in 2018. We early adopted the standard in the third quarter of 2017 on a retrospective basis. As a result, changes in restricted cash reported in 2016 as cash flows from investing activities are no longer reported as such. In August 2016, the FASB issued guidance intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flow, including the classification of (i) payments to extinguish debt and ( In March 2016, the FASB issued new guidance that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. The guidance also allows us to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting, clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on our cash flows statement, and provides an accounting policy election to account for forfeitures as they occur. We adopted the standard in the first quarter of 2017 and changed our accounting policy to recognize forfeitures as they occur. This change did not have a material effect on our results of operations as we previously did not apply an estimated forfeiture rate to restricted stock awards to our officers and directors. Additionally, most of our outstanding stock option awards vest on a monthly basis over the vesting period (generally three or four years). As these awards do not have performance conditions, the expense is recognized each month on a straight-line basis and excludes the effect of the estimated forfeiture rate as there was no risk of expensing awards that would be subsequently forfeited prior to vesting.

LOSS PER SHARE (EPS)

LOSS PER SHARE (EPS)	9 Months Ended
	Sep. 30, 2017
LOSS PER SHARE (EPS) [Abstract]
LOSS PER SHARE (EPS)	NOTE 5. LOSS PER SHARE (EPS) Basic EPS is calculated under the two-class method under which all earnings (distributed and undistributed) are allocated to each class of common stock and participating securities based on their respective rights to receive dividends. Our outstanding convertible preferred stocks are considered participating securities as the holders may participate in undistributed earnings with holders of common shares and are not obligated to share in our net losses. Diluted EPS is computed by dividing the net income attributable to RiceBran Technologies shareholders by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding if the impact of assumed exercises and conversions is dilutive. The dilutive effects of outstanding options, warrants, nonvested shares and restricted stock units that vest solely on the basis of a service condition are calculated using the treasury stock method. The dilutive effects of the outstanding preferred stock are calculated using the if-converted method. Below are reconciliations of the numerators and denominators in the continuing operations EPS computations for the three and nine months ended September 30, 2017 and 2016. Three Months Ended Nine Months Ended 2017 2016 2017 2016 NUMERATOR (in thousands): Basic and diluted - loss from continuing operations $ (4,199 ) $ (942 ) $ (8,387 ) $ (4,975 ) Dividend on preferred stock--beneficial conversion feature - - (778 ) (551 ) Basic and diluted - adjusted loss from continuing operations $ (4,199 ) $ (942 ) $ (9,165 ) $ (5,526 ) DENOMINATOR: Basic EPS - weighted average number of common shares outstanding 11,129,781 9,397,255 10,644,372 9,281,942 Effect of dilutive securities outstanding - - - - Diluted EPS - weighted average number of shares outstanding 11,129,781 9,397,255 10,644,372 9,281,942 Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive: Stock options 629,969 340,037 473,498 350,203 Warrants 22,824,888 10,842,006 21,306,727 10,132,045 Nonvested stock 1,301,725 1,114,747 1,236,241 1,038,019 Convertible preferred stock 2,128,180 2,000,000 3,020,739 1,611,722 Restricted stock unit awards 1,175,000 - 406,066 - The impact of potentially dilutive securities outstanding at September 30, 2017 and 2016, was not included in the calculation of the continuing operations diluted EPS for the three and nine months ended September 30, 2017 for the periods presented

CONCENTRATIONS OF RISK

CONCENTRATIONS OF RISK	9 Months Ended
	Sep. 30, 2017
CONCENTRATIONS OF RISK [Abstract]
CONCENTRATIONS OF RISK	NOTE 6. CONCENTRATIONS OF RISK Our trade accounts receivable subject us to significant concentrations of credit risk. We perform ongoing credit evaluations on our customers’ financial condition and generally do not require collateral. Revenues and accounts receivable from certain significant customers are stated below as a percent of continuing operations total revenue for the nine months ended September 30, 2017 % of Total Revenue Nine Months Ended % of Total Accounts Receivable Nine Months Ended Customer 2017 2016 2017 2016 Customer 1 17 % 12 % 31 % 28 % Customer 2 15 % 15 % * * Customer 3 * 12 % * * Customer 4 * * * * Customer 5 * * * 11 % Others 68 % 61 % 69 % 61 % Total 100 % 100 % 100 % 100 % * Less than 10% Purchases by continuing operations from certain significant suppliers are stated below as a percent of total purchases for the nine months ended September 30, 2017 % of Total Purchases Nine Months Ended Supplier 2017 2016 Supplier 1 * 13 % Supplier 2 * * Supplier 3 * * Supplier 4 * * Supplier 5 * * Others 100 % 87 % Total 100 % 100 % * Less than 10%

DEBT

DEBT	9 Months Ended
	Sep. 30, 2017
DEBT [Abstract]
DEBT	NOTE 7. DEBT The following table summarizes current and long-term portions of debt (in thousands): September 30, December 31, Senior debentures, net, maturing in February 2019, principal $6.6 million $ - $ - Subordinated notes, net, maturing in May 2019, principal $5.9 million - 6,310 Other 32 75 Senior revolving loan - 1,725 Senior term loan, net - 917 32 9,027 Current portion 19 3,063 Long-term portion $ 13 $ 5,964 We issued senior debentures in the principal amount of $6.6 million and related warrants in a private placement, in February 2017 . The transactions, and the accounting therefore, are Until July 2017, when we repaid the senior debentures and the subordinated notes in full with the proceeds from the sale of HN in July 2017, w . Upon extinguishment in July 2017, we recognized a loss on extinguishment of $6.6 million for the differences between (i) the $0.6 million carrying amount of the senior debentures and the $6.6 million face value paid and (ii) the $5.3 million carrying amount of the subordinated notes and the $6.0 million face value paid. In February 2017, we used the net proceeds from the senior debenture private placement discussed further in Note 8 to pay the senior revolving loan and the senior term loan in full.

EQUITY, SHARE-BASED COMPENSATIO

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS	9 Months Ended
	Sep. 30, 2017
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS	NOTE 8. EQUITY, SHARE-BASED COMPENSATION AND WARRANTS (in thousands) Shares Accumulated Deficit Attributable to Non-controlling Accumulated Other Comp- Preferred Preferred Common Accumulated Interest in rehensive Equity Series F Series G Common Stock Stock Deficit Nutra SA Loss (Deficit) Balance, December 31, 2016 - - 10,790,351 $ - $ 264,232 $ (259,819 ) $ (699 ) $ (4,346 ) $ (632 ) Issuance of common stock awards under equity incentive plans - - 642,839 - 817 - - - 817 Dividend on preferred stock - beneficial conversion feature - - - - 778 (778 ) - - - Modification of senior debenture holder warrants - - - - 582 - - - 582 Modification of subordinated note holder warrants - - - - 117 - - - 117 Change in classification of preferred stock to equity from liability 3,000 2,000 - 1,545 - - - - 1,545 Change in classification of warrants to equity from liability - - - - 7,851 - - - 7,851 Conversion of preferred stock into common stock (2,501 ) (700 ) 2,331,627 (807 ) 807 - - - - Proceeds from sale of common stock, net of costs - - 2,654,732 - 2,730 - - - 2,730 Exercise of warrant - - 103,008 - 101 - - - 101 Other - - 28,793 - 64 - - - 64 Proceeds from sale of membership interests - - - - - - 650 - 650 Foreign currency translation - - - - - - 38 93 131 Net loss - - - - - (205 ) (1,359 ) - (1,564 ) Balance, September 30, 2017 499 1,300 16,551,350 $ 738 $ 278,079 $ (260,802 ) $ (1,370 ) $ (4,253 ) $ 12,392 A summary of warrant activity for the nine months ended September 30, 2017, follows. Equity Warrants Liability Warrants Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding, December 31, 2016 6,364,110 $ 5.77 2.4 4,474,868 $ 1.82 3.3 Issued - NA NA 11,783,163 0.96 5.0 Impact of repricing debenture purchaser warrants: Prior to repricing (875,000 ) 5.49 2.1 - NA NA After repricing 875,000 0.96 5.5 - NA NA Impact of repricing subordinated note holder warants: Prior to repricing (289,669 ) 5.25 3.3 - NA NA After repricing 289,669 0.96 3.3 - NA NA Impact of anti-dilution clauses: Prior to impact - NA NA (1,489,868 ) 1.50 0.8 After impact - NA NA 2,327,919 0.96 0.8 Transfer from liability to equity 14,468,163 1.16 4.8 (14,468,163 ) 1.16 4.8 Exercised - NA NA (781,252 ) 0.96 - Forfeited, expired or cancelled - NA NA - NA NA Outstanding, September 30, 2017 20,832,273 $ 2.32 3.6 1,846,667 $ 1.06 0.7 Exercisable, September 30, 2017 20,832,273 $ 2.32 3.6 1,846,667 $ 1.06 0.7 Common Stock In February 2017, shareholders approved and we filed an amendment to our articles of incorporation increasing our authorized shares of common stock from 25,000,000 to 50,000,000. On February 14, 2017, we issued a former employee 108,696 shares of our common stock, in lieu of paying $100,000 cash for a 2016 bonus. In June 2017, we issued 96,372 shares of common stock as transitional director compensation to the chairman of our board, who was awarded transitional director compensation in the amount of (i) $10,000 or 7,035 shares per month for July 2016 through December 2016 and (ii) $8,333 or 9,027 shares per month for January 2017 through March 2017. The amount was payable in either cash or stock at the chairman’s election. The chairman elected to receive shares of common stock. In June 2017, we issued 345,205 shares of common stock to our directors at a grant date fair value of $0.90 per share. In August 2017, we issued 35,336 shares of common stock to a director at a grant date fair value of $1.09 per share. The restricted stock awards vest on the earlier of June 2018 or one day before the date of the next annual shareholder meeting. In the second quarter of 2017, we issued 220,439 shares of common stock upon conversion of 315 shares of Series F preferred stock and 11 shares of Series G preferred stock. We reclassified the $0.1 million carrying value of the related preferred stock to common stock. In September 2017, we issued and sold 2,654,732 shares of common stock for $1.08 per share. The net proceeds from the offering of $2.8 million, after deducting commissions and other cash offering expenses of $0.1 million, are included in common stock. We used the proceeds for general corporate purposes. In the third quarter of 2017, we issued 2,111,188 shares of common stock upon conversion of 2,186 shares of Series F preferred stock and 689 shares of Series G preferred stock. We reclassified the $0.7 million carrying value of the related preferred stock to common stock. In the fourth quarter of 2017, through the date of this filing, Share Sequencing From June 2015 until March 2017, the minority interest holders in Nutra SA could elect , the number of common stock and warrants issuable upon this election, was variable and indeterminate. For accounting purposes, we were not able to conclude that we had sufficient authorized and unissued shares to settle all contracts subject to the GAAP derivative guidance during the period the minority interest holders had this right, which terminated March 31, 2017. Our adopted sequencing approach (Share Sequencing) was based on earliest issuance date, therefore, we were required to carry warrants issued between June 2015 and March 2017, at fair value, as derivative warrant liabilities, and preferred stock issued between June 2015 and March 2017, Transactions with Preferred Stock Holders. In February 2017, we issued and sold 2,000 shares of Series G preferred stock. The Series G preferred stock is non-voting and may be converted into a total of 1,897,983 shares of our common stock at the holders’ election at any time, subject to certain beneficial ownership limitations, at a ratio of 1 preferred share for 948.9915 shares of common stock. The Series G preferred stock is entitled to receive dividends if we pay dividends on our common stock, in which case the holders of Series G preferred stock are entitled to receive the amount and form of dividends that they would have received if they held the common stock that is issuable upon conversion of the Series G preferred stock. If we are liquidated or dissolved, the holders of Series G preferred stock are entitled to receive, before any amounts are paid in respect of our common stock, an amount per share of Series G preferred stock equal to $1,000, plus any accrued but unpaid dividends thereon. In February 2017, in conjunction with the sale of the Series G preferred stock, we also sold warrants to purchase 1,423,488 shares of common stock (exercise price of $0.96 per share, exercisable beginning in February 2017 and expiring in February 2022). A subordinated note holder exchanged subordinated notes with a principal and carrying value of $0.1 million and cash for 180 shares of the Series G preferred stock and related warrants, which was treated as an extinguishment of debt. The net cash proceeds from the sale was $1.7 million, after deducting allocated cash offering expenses of $0.1 million. On the date of issuance, we allocated $1.0 million of the proceeds to derivative warrant liability, to record the warrants at fair value, recorded a $0.1 million loss on extinguishment and reduced debt $0.1 million related to the subordinated noteholders exchange, and recorded $1.2 million as preferred stock. We recorded a $0.8 million dividend on preferred stock for the preferred stock beneficial conversion feature equal to the proceeds allocated to the preferred stock issued to purchases who did not exchange debt, as the fair value of the common stock underlying the convertible preferred stock at issuance exceeded the amount recorded in preferred stock. Transactions with Senior Debenture Holders In February 2017, we sold and issued in a private placement, for an aggregate subscription amount of $6.0 million: (i) senior debentures in the principal amount of $6.6 million and (ii) warrants to purchase an aggregate of 6,875,000 shares of common stock (exercise price of $0.96 per share, exercisable beginning February 2017 and expiration February 2022). We received aggregate net proceeds of $5.5 million, after deducting placement agent fees and allocated expenses of $0.5 million. Concurrently, we amended existing warrants, held by the debenture purchasers, for the purchase of up to 875,000 shares to (i) reduce the exercise prices from an average $5.49 per share to $0.96 per share, providing the warrants are not exercisable until August 2017, and (ii) change the expiration dates to August 2022, which increased the average remaining term of the warrants from 2.1 years to 5.5 years. We recorded $4.6 million as an increase to derivative warrant liabilities, to record the warrants at their fair value on the date of issuance, the $0.5 million as an increase in common stock to record the change in fair value of existing warrants and the remaining $0.4 million to debt, debt issuance costs and debt discount. We used the net proceeds from the offering to (i) pay off the senior revolving loan and term loan debt totaling $3.8 million and (ii) pay $0.2 million of principal and $0.3 million of interest due on subordinated notes and (iii) for working capital and general corporate purposes. We filed a registration statement on Form S-3, which became effective in May 2017, to register the shares under the warrants issued to the senior debenture purchasers. Transaction with Subordinated Note Holders In connection with the February 2017 senior debenture private placement, we entered into agreements which resulted in (i) a reduction in the annual interest rate on the subordinated notes from 11.75% to 7% (ii) an extension of the maturity date of the subordinated notes to May 2019 from May 2018 (iii) the payment of an aggregate amount equal to $0.5 million on the subordinated notes; (iv) the issuance of warrants to purchase up to 3,484,675 shares of our common stock (exercise price of $0.96 per share, expiration February 2022); and (v) the amendment of existing warrants held by the subordinated note holders for the purchase 289,669 shares of common stock to reduce the exercise price from $5.25 per share to $0.96 per share. We accounted for the transaction as an extinguishment of debt and issuance of new debt. In February 2017, we (i) recorded a loss on extinguishment of debt of $1.5 million, (ii) adjusted subordinated notes payable debt down by $0.9 million, to its fair value as of the transaction date, (iii) increased derivative liability $2.3 million, representing the fair value of the newly issued warrants, and (iv) increased common stock equity by $0.1 million for the change in the fair value of the existing warrants. Full Ratchet Anti-Dilution As a result of the February 2017 transactions described above, the exercise price of certain warrants that contain full ratchet anti-dilution provisions was reduced from $1.50 per share to $0.96 per share and the number of shares of common stock underlying these warrants increased from 1,489,868 shares to 2,327,919 shares. In the third quarter of 2017, the holder exercised one of the warrants, for the purchase 781,252 shares, into common stock. Equity Incentive Plan In June 2017, shareholders approved a 1,700,000 increase in the authorized shares issuable under the 2014 Equity Incentive Plan (the 2014 Plan). The total shares authorized under the 2014 Plan is now 3,300,000 shares. Option Issuances In the first quarter of 2017, we granted our chief executive officer an option to purchase 100,000 shares of our common stock at an exercise price of $0.76 per share. The option vested as to 25,000 shares in August 2017, the remaining shares in monthly installments through August 2020 and the option had a grant date fair value of $0.56 per share. In the second quarter of 2017, we granted options to purchase an aggregate 355,500 shares of our common stock to executive officers and employees at an average exercise price of $0.85 per share. The options vest in four equal annual installments beginning in the second quarter of 2018 and had a grant date fair value of $0.62 per share. In the third quarter of 2017, we granted an option to purchase an aggregate 20,000 shares of our common stock to an employee at an exercise price of $1.09 per share. The option vests in four equal annual installments beginning in the third quarter of 2018 and had a grant date fair value of $0.77 per share. Restricted Stock Unit Awards In late June 2017, we issued restricted stock units (RSUs), under the 2014 Plan, to our executive officers covering a total of 1,175,000 shares of our common stock. The shares subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days. Each RSU’s shares vest (i) 10% if the vesting price equals or exceeds $5.00 per share, (ii) 30% if the vesting price equals or exceeds $10.00 per share and (iv) 60% if the vesting price equals or exceeds $15.00 per share. The shares had a grant date fair value of $0.2 million which is being expensed ratably over a 3.5-year period beginning in July 2017. Warrants In July 2017, the holder of a liability warrant to purchase 781,252 shares, at an exercise price of $0.96 per share, exercised the warrant into common stock with a fair value on the date of the conversion of $0.98 per share. We issued 103,008 shares of common stock to the holder in a cashless transaction and recorded a $0.1 million loss on the conversion equal to the difference between the fair value of the liability and the fair value of the common stock on the date of the conversion. The following table summarizes information related to outstanding warrants as September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Range of Exercise Prices Type of Warrant Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Under Warrants, Exercisable Cashless Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) (4 ) $ 0.96 Liability (1) 1,546,667 $ 0.96 0.4 1,546,667 - $ - - $ 0.96 Equity 12,947,832 0.96 4.6 3,774,344 - - - $ 1.50 Liability (2) 300,000 1.60 2.9 300,000 - - - $ 1.50 to $1.60 Liability - - - - 1,789,868 1.52 1.3 $ 2.00 Liability (3) - - - - 2,660,000 2.00 4.6 $ 2.00 Equity 2,660,000 2.00 4.2 - - - - $ 5.25 Liability (3) - - - - 25,000 5.25 3.6 $ 5.25 to $5.87 Equity 3,156,670 5.33 2.2 359,536 4,296,339 5.36 2.7 $ 6.55 to $16.80 Equity 2,067,771 6.61 1.5 190,899 2,067,771 6.61 2.0 22,678,940 $ 2.21 3.6 6,171,446 10,838,978 $ 4.14 2.8 (1) Includes one warrant which contains full ratchet anti-dilution provisions and is classified as derivative warrant liabilities in our balance sheet. Under the anti-dilution clause contained in this warrant, in the event of equity issuances (i.e. issuances of our common stock, certain awards of stock options to employees, and issuances of warrants and/or other convertible instruments) at prices below the exercise price of this warrant, we are required to lower the exercise price on this warrant and increase the number of shares underlying this warrant. (2) Includes a warrant to purchase of 300,000 shares of our common stock which contains a most favored nations anti-dilution provision. Under that provision, in the event we issue warrants and/or other convertible instruments with anti-dilution provisions with respect to the exercise price of the warrant or the conversion price of the convertible instrument, we will be required to provide the same anti-dilution provision in this warrant and may be required to lower the exercise price on this warrant and/or increase the number of shares underlying this warrant. (3) The warrants were classified as derivative warrant liabilities in our balance sheets due to the Share Sequencing as of December 31, 2016, and were reclassified to equity (deficit) effective March 31, 2017. (4) Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature. The shares listed, represent the shares holders could exercise cashless as of September 30, 2017. If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise. Should we fail to maintain a registration statement for the resale of shares under certain other warrant, the shares under those warrants may be exercisable using a cashless exercise feature.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2017
FAIR VALUE MEASUREMENTS [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 9. FAIR VALUE MEASUREMENTS The fair value of cash and cash equivalents, accounts and other receivables and accounts payable approximates their carrying value due to their shorter maturities. As of September 30, 2017, the fair value of our debt (Level 3 measurement) approximated its carrying value, based on current market rates for similar debt with similar maturities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Certain assets and liabilities are presented in the financial statements at fair value. Assets and liabilities measured at fair value on a recurring basis include derivative warrant and conversion liabilities. Assets and liabilities measured at fair value on a non-recurring basis may include property. We assess the inputs used to measure fair value using a three-tier hierarchy based on the extent to which inputs used in measuring fair value are observable in the market: ● Level 1 – inputs include quoted prices for identical instruments and are the most observable. ● Level 2 – inputs include quoted prices for similar assets and observable inputs such as interest rates, currency exchange rates and yield curves. ● Level 3 – inputs are not observable in the market and include management’s judgments about the assumptions market participants would use in pricing the asset or liability. For instruments measured using Level 3 inputs, a reconciliation of the beginning and ending balances is disclosed. The following tables summarize the fair values by input hierarchy of items measured at fair value on a recurring basis on our condensed consolidated balance sheets (in thousands). Level 1 Level 2 Level 3 Total Total liabilities at fair value, as of September 30, 2017 - derivative warrant liabilities $ - $ - $ 769 $ 769 Total liabilities at fair value, as of December 31, 2016 - derivative warrant liabilities $ - $ - $ 1,527 $ 1,527 Warrants accounted for as derivative liabilities are valued using the lattice model each reporting period and the resultant change in fair value is recorded in the consolidated statements of operations. The lattice model requires us to assess the probability of future issuance of equity instruments at a price lower than the current exercise price of the warrants. The risk-free interest rate is determined by reference to the treasury yield curve rate of instruments with the same term as the warrant. Additional assumptions that were used to calculate fair value follow. September 30, 2017 December 31, 2016 Risk-free interest rate 1.2% 0.6% -1.9% (1.2% weighted average) (1.6% weighted average) Expected volatility 67%-72% 64% (71% weighted average) (64% weighted average) The following tables summarize the changes in Level 3 items measured at fair value on a recurring basis (in thousands): Total Level 3 Fair Value Fair Value as of Beginning of Period Total Realized and Unrealized Gains (Losses) Issuance of New Instruments Reclassify to (Deficit) Equity Conversion to Common Stock Fair Value, at End of Period (1) Nine Months Ended September 30, 2017, derivative warrant liabilities $ (1,527 ) $ 808 $ (7,917 ) $ 7,851 $ 16 $ (769 ) Nine Months Ended September 30, 2016, derivative warrant liabilities $ (678 ) $ 314 $ (2,474 ) $ - $ - $ (2,838 ) (1) Included in change in fair value of derivative warrant liabilities in our consolidated statements of operations.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2017
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 10. COMMITMENTS AND CONTINGENCIES In addition to the matters discussed below, from time to time we are involved in litigation incidental to the conduct of our business in the USA and Brazil. These matters may relate to employment and labor claims, patent and intellectual property claims, claims of alleged non-compliance with contract provisions and claims related to alleged violations of laws and regulations. When applicable, we record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations. Defense costs are expensed as incurred and are included in professional fees. Irgovel Litigation Irgovel is a defendant in several labor claims, mainly related to overtime, illnesses allegedly contracted at work and work-related injuries and salary related matters for periods prior to the acquisition of Irgovel by RiceBran. The labor suits are mainly in the lower courts, and for the majority of the cases a decision for the dismissal of the claims has been granted. None of these labor claims is individually significant. Management believes it’s unlikely there will be a judgment against Irgovel, however, in the event the court does issue a judgment against Irgovel, it could be approximately $1.1 million. Irgovel accrues for losses on tax and other legal contingencies when it has a present obligation, formalized or not, as a result of a past event, it is probable that an outflow of resources will be required to settle the obligation and the amount of the obligation can be reliably estimated. Irgovel is a party to several other pending litigations and administrative proceedings at the Federal, State and Municipal level. The assessment of the likelihood of an unfavorable outcome in these litigations and proceedings includes the analysis of the evidence available, the hierarchy of the applicable laws, available former court decisions, as well as the most recent court decisions and their importance to the Brazilian legal system, as well as the opinions of our external and in-house legal counsels. We record amounts considered sufficient by our management to cover probable losses based on these elements. In addition to the above items, Irgovel has a contingent liability of approximately $0.3 million for amounts claimed to be owed in connection with a loan agreement entered into in April 2007 between Irgovel and a former shareholder of Irgovel. In April 2014, the former shareholder filed an enforcement action against Irgovel to collect such amounts. In June 2014, Irgovel filed a motion to annul the enforcement proceedings. The enforcement proceedings were dismissed in September 2015. In May 2016, the court found in favor of the former shareholder to appeal the stay of execution that was previously granted. Irgovel - Events of Default As further described in Note 2, Irgovel is required to meet minimum annual processing targets or to achieve EBITDA on a local currency basis of at least R$4.0 million annually. If not achieved, this would result in an event of default under our existing agreements with the Investors. It is possible that an event of default may be triggered as of December 31, 2017, and a waiver of non-compliance may not be obtained from the Investors. Employment Contracts and Severance Payments We have employment contracts with certain officers and key management that include provisions for potential severance payments in the event of without-cause terminations or terminations under certain circumstances after a change in control. In addition, vesting of outstanding unvested equity grants held by these individuals would accelerate following a change in control.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2017
INCOME TAXES [Abstract]
INCOME TAXES	NOTE 11. INCOME TAXES We expect to have sufficient net operating losses to offset the taxable gain related to the sale of HN and HN’s taxable operating income in 2017. Alternative minimum tax may be due on the sale of HN based on the calculation of alternative minimum taxable income, which allows taxable income to only be offset 90% by net operating loss carryforwards; thereby potentially leaving residual taxable income of 10%, subject to a rate of 20%. We currently estimate $0.3 million to be payable under the alternative minimum tax but we will continue to evaluate the use of additional current year operating losses to offset the taxable income. We have determined that a Section 382 ownership change occurred in September 2017 and our ability to carryforward remaining net operating losses subsequent to the most recent change in ownership will be severely limited. The Internal Revenue Service rules in this area are complex and our estimates are subject to change.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2017
RELATED PARTY TRANSACTIONS [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 12. RELATED PARTY TRANSACTIONS Prior to 2017, entities beneficially owned by Baruch Halpern, a director, invested in our subordinated notes and related warrants prior to 2014. As of September 30, 2017, and throughout the first six months of 2017, Mr. Halpern beneficially held approximately 43% of our outstanding subordinated notes and related warrants. See Note 8 for information related to the modification of the subordinated notes, repricing of related warrants and the issuance of warrants to subordinated note holders in February 2017. The notes were paid in full in July 2017 from the proceeds of the sale of HN. In the three months ended September 30, 2017 and 2016, we expensed $0.1 million of interest on the subordinated notes beneficially owned by Mr. Halpern. In the nine months ended September 30, 2017 and 2016, we expensed $0.2 million of interest on the subordinated notes. As discussed in Note 8, in September 2017, we issued and sold 2,654,732 shares of common stock to Continental Grain Company (CGG). Our director, Ari Gendason is an employee and senior vice president -corporate investments of CGG. As of the date of this filing greed that in connection with each annual or special meeting of our shareholders at which members of our board of directors are to be elected, or any written consent of our shareholders pursuant to which members of the board of directors are to be elected, CGC shall have the right to designate one nominee to our board of directors.

FAILURE TO COMPLY WITH NASDAQ L

FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS	9 Months Ended
	Sep. 30, 2017
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS [Abstract]
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS	NOTE 13. FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS On August 18, 2016, we received a notification letter from The Nasdaq Stock Market LLC (Nasdaq) indicating that we have failed to comply with the minimum stockholders’ equity requirement of Nasdaq Listing Rule 5550(b)(1). Nasdaq Listing Rule 5550(b)(1) requires that companies listed on the Nasdaq Capital Market maintain a minimum of $2.5 million in stockholders’ equity for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1) We submitted our plan to regain compliance in October 2016. On November 15, 2016, Nasdaq granted us a 180-day extension to February 14, 2017 to evidence compliance with the minimum stockholders’ equity requirement. On February 16, 2017, we received a determination letter from Nasdaq stating that we had not regained compliance with the minimum stockholders’ equity requirement. The letter also stated our common stock would be delisted from The Nasdaq Capital Market at the opening of business on February 27, 2017 unless we request a hearing before the Nasdaq Hearing Panel. We requested and were granted a hearing before the panel to appeal the determination letter on March 30, 2017. After that hearing, o n April 24, 2017, we received a decision letter from Nasdaq stating that the panel granted the request we made at the hearing for continued listing provided that, on or before May 15, 2017, we have announced that our equity is over $2.5 million (it was $7.9 million as of March 31, 2017). As reported herein our equity is $12.4 million and exceeds the minimum as of September 30, 2017. On March 10, 2017, we received a notification letter from Nasdaq indicating that we have failed to comply with the minimum bid price requirement of Nasdaq List Rule 5550(a)(2) because our common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive trading days. On August 1, 2017, we received a notification letter from Nasdaq that we regained compliance with Nasdaq List Rule 5550(a)(2) minimum bid price requirement by meeting the closing bid price of $1.00 or more for 10 consecutive trading days on July 31, 2017.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Sep. 30, 2017
BASIS OF PRESENTATION [Abstract]
BASIS OF PRESENTATION	In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q; therefore, as permitted under these rules, certain footnotes and other financial information included in complete financial statements were condensed or omitted. The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented. These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2016. The report of our independent registered public accounting firm that accompanies the audited consolidated financial statements for the year ended December 31, 2016, included in that Annual Report on Form 10-K, contains a going concern explanatory paragraph in which our independent registered public accounting firm expressed substantial doubt about our ability to continue as a going concern. The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared assuming we will continue as a going concern based on the realization of assets and the satisfaction of liabilities in the normal course of business.

RECENT ACCOUNTING GUIDANCE (Pol

RECENT ACCOUNTING GUIDANCE (Policies)	9 Months Ended
	Sep. 30, 2017
RECENT ACCOUNTING GUIDANCE [Abstract]
RECENT ACCOUNTING GUIDANCE	Recent accounting standards not yet adopted In May 2014, the Financial Accounting Standards Board (FASB) issued guidance on revenue from contracts with customers to clarify the principles for recognizing revenue and develop a common revenue standard for GAAP and International Financial Reporting Standards. Under the new guidance, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services, applying the following steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. An entity may choose to adopt the new standard either retrospectively or through a cumulative effect adjustment as of the start of the first period for which it applies the new standard. The guidance is effective for our annual and interim periods beginning in 2018, however, early adoption is permitted. We have begun to evaluate the impact that adoption of this guidance will have on our consolidated financial statements but have not completed the evaluation and implementation process. We expect to transition through a cumulative effect adjustment as of January 1, 2018. Under the modified retrospective method adoption will have no impact on reported results of operations, financial position and cash flows of discontinued operations, with respect to HN, because we no longer reflect HN operations in our consolidated results after the sale of HN in July 2017. Similarly, if we dispose of Nutra SA, before December 31, 2017, we expect adoption will have no impact on reported results of operations, financial position and cash flows of discontinued operations, with respect to Nutra SA as well. In February 2016, the FASB issued guidance which changes the accounting for leases. Under prior GAAP, the recognition, measurement and presentation of expenses and cash flows arising from a lease for us as a lessee depend primarily on the lease’s classification as a finance or operating lease. For both types of leases, lessees will recognize a right-of-use asset and a lease liability. For capital or finance leases, lessees will recognize amortization of the right-of-use asset separately from interest expense on the lease liability. The guidance is effective for our annual and interim periods beginning in 2019 and must be adopted on a modified retrospective approach. Early adoption is allowed. We have not yet determined the impact that the new guidance will have on our results of operations, financial position and cash flows and have not yet determined if we will early adopt the standard. Recently adopted accounting standards In May 2017, the FASB issued guidance that clarifies the scope of asset derecognition guidance and accounting for partial sales of nonfinancial assets. We adopted the standard early, as of January 1, 2017, with no effect on our financial position or results of operations. In February 2017, the FASB issued guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. We adopted the standard early, as of January 1, 2017, with no effect on our financial position or results of operations. In January 2017, the FASB issued a new goodwill impairment standard that simplifies the goodwill impairment testing methodology. The new standard eliminates Step 2 of the goodwill impairment test, in which an entity determines the fair value at the test date of its assets and liabilities using the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. We adopted the standard early, as of January 1, 2017, with no effect on our financial position or results of operations. In November 2016, the FASB issued guidance that requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. We were required to adopt the guidance for our annual and interim periods beginning in 2018. We early adopted the standard in the third quarter of 2017 on a retrospective basis. As a result, changes in restricted cash reported in 2016 as cash flows from investing activities are no longer reported as such. In August 2016, the FASB issued guidance intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flow, including the classification of (i) payments to extinguish debt and ( In March 2016, the FASB issued new guidance that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. The guidance also allows us to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting, clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on our cash flows statement, and provides an accounting policy election to account for forfeitures as they occur. We adopted the standard in the first quarter of 2017 and changed our accounting policy to recognize forfeitures as they occur. This change did not have a material effect on our results of operations as we previously did not apply an estimated forfeiture rate to restricted stock awards to our officers and directors. Additionally, most of our outstanding stock option awards vest on a monthly basis over the vesting period (generally three or four years). As these awards do not have performance conditions, the expense is recognized each month on a straight-line basis and excludes the effect of the estimated forfeiture rate as there was no risk of expensing awards that would be subsequently forfeited prior to vesting.

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	9 Months Ended
	Sep. 30, 2017
Healthy Natural Inc [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Summary of other data	The following table summarizes other data for HN (in thousands). Three Months Ended Nine Months Ended 2017 2016 2017 2016 Depreciation included in cost of goods sold $ 7 $ 42 $ 96 $ 130 Depreciation included in selling, general and administrative expenses 4 20 49 58 Amortization included in selling, gneral and administrative expenses - 204 - 659 Capital expenditures 3 22 18 95
Income (loss) from discontinued operations	The following table summarizes the major line items included in the income (loss) from discontinued operations for the divestiture of HN (in thousands). Three Months Ended Nine Months Ended 2017 2016 2017 2016 Revenues $ 421 $ 5,010 $ 9,902 $ 15,044 Cost of goods sold (293 ) (3,330 ) (6,651 ) (9,991 ) Selling, general and administrative expenses (19 ) (396 ) (462 ) (1,100 ) Income from operations, before income taxes 109 1,284 2,789 3,953 Income tax expense (36 ) (437 ) (948 ) (1,344 ) Income from operations, net of tax 73 847 1,841 2,609 Gain on sale, net of $4.3 million income tax expense 8,845 - 8,845 - Income from discontinued operations, net of tax $ 8,918 $ 847 $ 10,686 $ 2,609
Assets and liabilities classified as held for sale	The following table summarizes the estimated carrying amount of HN as of the July 2017 sale (in thousands). Accounts receivable, net $ 871 Inventories 1,987 Other current assets 47 Property and equipment 871 Intangible 791 Other 24 Assets 4,591 Accounts payable 759 Accrued expenses 290 Liabilities 1,049 Net assets sold $ 3,542 The following table summarizes the carrying amounts of major classes of HN assets and liabilities classified as held for sale as of December 31, 2016 (in thousands). December 31, Accounts receivable, net $ 592 Inventories 1,915 Other current assets held for sale 23 Property and equipment 1,019 Intangible 791 Other noncurrent assets 24 Total assets held for sale $ 4,364 Accounts payable $ 443 Accrued expenses 382 Long term liabilities 44 Total liabilities held for sale $ 869
Cash flows from discontinued operations	The following table summarizes the major line items included in cash flows from discontinued operations of HN for the nine months ended September 30, 2017 and 2016 (in thousands). Nine Months Ended 2017 2016 Net cash provided by operating activities $ 2,803 $ 3,701 Net cash provided by (used in) investing activities 16,719 (73 ) Net cash used in financing activities (48 ) - Net cash provided to continuing operations $ (19,474 ) $ (3,628 )
Nutra SA [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Summary of other data	The following table summarizes other data for Nutra SA (in thousands). Three Months Ended Nine Months Ended 2017 2016 2017 2016 Depreciation included in cost of goods sold $ 274 $ 246 $ 792 $ 672 Depreciation included in selling, general and administrative expenses 15 16 46 42 Capital expenditures 22 1 115 157
Income (loss) from discontinued operations	The following table summarizes the major line items included in income (loss) from discontinued operations for Nutra SA in the three and nine months ended September 30, 2017 and 2016 (in thousands). Three Months Ended Nine Months Ended 2017 2016 2017 2016 Revenues $ 3,226 $ 563 $ 9,589 $ 4,627 Cost of goods sold (3,539 ) (1,154 ) (9,814 ) (6,103 ) Selling, general and administrative expenses (1,541 ) (509 ) (2,572 ) (1,891 ) Goodwill impairment - - - (3,024 ) Other expense (358 ) (355 ) (1,066 ) (1,047 ) Loss from discontinued operations, before income taxes (2,212 ) (1,455 ) (3,863 ) (7,438 ) Income taxes - - - - Loss from discontinued operations, net of tax $ (2,212 ) $ (1,455 ) $ (3,863 ) $ (7,438 )
Assets and liabilities classified as held for sale	The following table summarizes the carrying amounts of major classes of Nutra SA assets and liabilities classified as held for sale (in thousands). September 30, December 31, Cash and cash equivalents $ 54 $ 109 Accounts receivable, net (restricted) 781 398 Inventories 1,237 925 Other current asssets 326 373 Property and equipment, net (restricted $2,662 and $2,599) 10,464 10,889 Other noncurrent assets 1,321 1,327 Total assets held for sale $ 14,183 $ 14,021 Accounts payable $ 2,338 $ 2,553 Accrued expenses 8,274 5,607 Current maturities of long-term debt (nonrecourse) 7,627 6,816 Total liabilities held for sale $ 18,239 $ 14,976
Cash flows from discontinued operations	The following table summarizes the major line items included in cash flows from Nutra SA discontinued operations for the nine months ended September 30, 2017 and 2016 (in thousands). Nine Months Ended 2017 2016 Net cash used in operating activities $ (1,345 ) $ (9 ) Net cash used in investing activities (115 ) (157 ) Net cash provided (used) by financing activities 1,280 (551 ) Net cash provided by continuing operations - 863 Effect of exchange rate changes 125 (183 ) Net change in cash and cash equivalents (55 ) (37 ) Cash and cash equivalents, beginning of period 109 104 Cash and cash equivalents, end of period $ 54 $ 67
Components of debt	Nutra SA’s debt consists of the following (in thousands): September 30 December 31, Capital expansion loans $ 2,635 $ 2,454 Working capital lines of credit 1,081 401 Advances on customer export orders 785 1,113 Special tax programs 3,014 2,767 Other 112 81 $ 7,627 $ 6,816
Summary of changes in redeemable noncontrolling interest in discontinued operations	A summary of changes in redeemable noncontrolling interest in Nutra SA, reflected as accumulated deficit attributable to noncontrolling interest in discontinued operations, in the accompanying condensed consolidated balance sheets, for the three and nine months ended September 30, 2017 and 2016 (in thousands) follows. Three Months Ended Nine Months Ended 2017 2016 2017 2016 Redeemable noncontrolling interest in Nutra SA, beginning of period $ (567 ) $ (1,599 ) $ (699 ) $ 69 Investors' interest in net loss of Nutra SA (792 ) (470 ) (1,359 ) (2,416 ) Investors' interest in other comprehensive loss of Nutra SA (11 ) (60 ) 38 218 Investors purchase of additional membership interest - 200 650 200 Redeemable noncontrolling interest in Nutra SA, end of period $ (1,370 ) $ (1,929 ) $ (1,370 ) $ (1,929 ) Investors' average interest in Nutra SA during the period 35.8 % 32.5 % 35.5 % 32.2 % Investors' interest in Nutra SA at the end of the period 35.8 % 32.7 % 35.8 % 32.7 %

LOSS PER SHARE (EPS) (Tables)

LOSS PER SHARE (EPS) (Tables)	9 Months Ended
	Sep. 30, 2017
LOSS PER SHARE (EPS) [Abstract]
Reconciliations of numerators and denominators in EPS computations	Below are reconciliations of the numerators and denominators in the continuing operations EPS computations for the three and nine months ended September 30, 2017 and 2016. Three Months Ended Nine Months Ended 2017 2016 2017 2016 NUMERATOR (in thousands): Basic and diluted - loss from continuing operations $ (4,199 ) $ (942 ) $ (8,387 ) $ (4,975 ) Dividend on preferred stock--beneficial conversion feature - - (778 ) (551 ) Basic and diluted - adjusted loss from continuing operations $ (4,199 ) $ (942 ) $ (9,165 ) $ (5,526 ) DENOMINATOR: Basic EPS - weighted average number of common shares outstanding 11,129,781 9,397,255 10,644,372 9,281,942 Effect of dilutive securities outstanding - - - - Diluted EPS - weighted average number of shares outstanding 11,129,781 9,397,255 10,644,372 9,281,942 Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive: Stock options 629,969 340,037 473,498 350,203 Warrants 22,824,888 10,842,006 21,306,727 10,132,045 Nonvested stock 1,301,725 1,114,747 1,236,241 1,038,019 Convertible preferred stock 2,128,180 2,000,000 3,020,739 1,611,722 Restricted stock unit awards 1,175,000 - 406,066 -

CONCENTRATIONS OF RISK (Tables)

CONCENTRATIONS OF RISK (Tables)	9 Months Ended
	Sep. 30, 2017
CONCENTRATIONS OF RISK [Abstract]
Concentrations of risk	Revenues and accounts receivable from certain significant customers are stated below as a percent of continuing operations total revenue for the nine months ended September 30, 2017 % of Total Revenue Nine Months Ended % of Total Accounts Receivable Nine Months Ended Customer 2017 2016 2017 2016 Customer 1 17 % 12 % 31 % 28 % Customer 2 15 % 15 % * * Customer 3 * 12 % * * Customer 4 * * * * Customer 5 * * * 11 % Others 68 % 61 % 69 % 61 % Total 100 % 100 % 100 % 100 % * Less than 10% Purchases by continuing operations from certain significant suppliers are stated below as a percent of total purchases for the nine months ended September 30, 2017 % of Total Purchases Nine Months Ended Supplier 2017 2016 Supplier 1 * 13 % Supplier 2 * * Supplier 3 * * Supplier 4 * * Supplier 5 * * Others 100 % 87 % Total 100 % 100 % * Less than 10%

DEBT (Tables)

DEBT (Tables)	9 Months Ended
	Sep. 30, 2017
DEBT [Abstract]
Current and long-term debt	The following table summarizes current and long-term portions of debt (in thousands): September 30, December 31, Senior debentures, net, maturing in February 2019, principal $6.6 million $ - $ - Subordinated notes, net, maturing in May 2019, principal $5.9 million - 6,310 Other 32 75 Senior revolving loan - 1,725 Senior term loan, net - 917 32 9,027 Current portion 19 3,063 Long-term portion $ 13 $ 5,964

EQUITY, SHARE-BASED COMPENSAT26

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2017
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]
Summary of equity activity	Shares Accumulated Deficit Attributable to Non-controlling Accumulated Other Comp- Preferred Preferred Common Accumulated Interest in rehensive Equity Series F Series G Common Stock Stock Deficit Nutra SA Loss (Deficit) Balance, December 31, 2016 - - 10,790,351 $ - $ 264,232 $ (259,819 ) $ (699 ) $ (4,346 ) $ (632 ) Issuance of common stock awards under equity incentive plans - - 642,839 - 817 - - - 817 Dividend on preferred stock - beneficial conversion feature - - - - 778 (778 ) - - - Modification of senior debenture holder warrants - - - - 582 - - - 582 Modification of subordinated note holder warrants - - - - 117 - - - 117 Change in classification of preferred stock to equity from liability 3,000 2,000 - 1,545 - - - - 1,545 Change in classification of warrants to equity from liability - - - - 7,851 - - - 7,851 Conversion of preferred stock into common stock (2,501 ) (700 ) 2,331,627 (807 ) 807 - - - - Proceeds from sale of common stock, net of costs - - 2,654,732 - 2,730 - - - 2,730 Exercise of warrant - - 103,008 - 101 - - - 101 Other - - 28,793 - 64 - - - 64 Proceeds from sale of membership interests - - - - - - 650 - 650 Foreign currency translation - - - - - - 38 93 131 Net loss - - - - - (205 ) (1,359 ) - (1,564 ) Balance, September 30, 2017 499 1,300 16,551,350 $ 738 $ 278,079 $ (260,802 ) $ (1,370 ) $ (4,253 ) $ 12,392
Summary of warrant activity	A summary of warrant activity for the nine months ended September 30, 2017, follows. Equity Warrants Liability Warrants Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding, December 31, 2016 6,364,110 $ 5.77 2.4 4,474,868 $ 1.82 3.3 Issued - NA NA 11,783,163 0.96 5.0 Impact of repricing debenture purchaser warrants: Prior to repricing (875,000 ) 5.49 2.1 - NA NA After repricing 875,000 0.96 5.5 - NA NA Impact of repricing subordinated note holder warants: Prior to repricing (289,669 ) 5.25 3.3 - NA NA After repricing 289,669 0.96 3.3 - NA NA Impact of anti-dilution clauses: Prior to impact - NA NA (1,489,868 ) 1.50 0.8 After impact - NA NA 2,327,919 0.96 0.8 Transfer from liability to equity 14,468,163 1.16 4.8 (14,468,163 ) 1.16 4.8 Exercised - NA NA (781,252 ) 0.96 - Forfeited, expired or cancelled - NA NA - NA NA Outstanding, September 30, 2017 20,832,273 $ 2.32 3.6 1,846,667 $ 1.06 0.7 Exercisable, September 30, 2017 20,832,273 $ 2.32 3.6 1,846,667 $ 1.06 0.7
Summary of outstanding warrants	The following table summarizes information related to outstanding warrants as September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Range of Exercise Prices Type of Warrant Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Under Warrants, Exercisable Cashless Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) (4 ) $ 0.96 Liability (1) 1,546,667 $ 0.96 0.4 1,546,667 - $ - - $ 0.96 Equity 12,947,832 0.96 4.6 3,774,344 - - - $ 1.50 Liability (2) 300,000 1.60 2.9 300,000 - - - $ 1.50 to $1.60 Liability - - - - 1,789,868 1.52 1.3 $ 2.00 Liability (3) - - - - 2,660,000 2.00 4.6 $ 2.00 Equity 2,660,000 2.00 4.2 - - - - $ 5.25 Liability (3) - - - - 25,000 5.25 3.6 $ 5.25 to $5.87 Equity 3,156,670 5.33 2.2 359,536 4,296,339 5.36 2.7 $ 6.55 to $16.80 Equity 2,067,771 6.61 1.5 190,899 2,067,771 6.61 2.0 22,678,940 $ 2.21 3.6 6,171,446 10,838,978 $ 4.14 2.8 (1) Includes one warrant which contains full ratchet anti-dilution provisions and is classified as derivative warrant liabilities in our balance sheet. Under the anti-dilution clause contained in this warrant, in the event of equity issuances (i.e. issuances of our common stock, certain awards of stock options to employees, and issuances of warrants and/or other convertible instruments) at prices below the exercise price of this warrant, we are required to lower the exercise price on this warrant and increase the number of shares underlying this warrant. (2) Includes a warrant to purchase of 300,000 shares of our common stock which contains a most favored nations anti-dilution provision. Under that provision, in the event we issue warrants and/or other convertible instruments with anti-dilution provisions with respect to the exercise price of the warrant or the conversion price of the convertible instrument, we will be required to provide the same anti-dilution provision in this warrant and may be required to lower the exercise price on this warrant and/or increase the number of shares underlying this warrant. (3) The warrants were classified as derivative warrant liabilities in our balance sheets due to the Share Sequencing as of December 31, 2016, and were reclassified to equity (deficit) effective March 31, 2017. (4) Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature. The shares listed, represent the shares holders could exercise cashless as of September 30, 2017. If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise. Should we fail to maintain a registration statement for the resale of shares under certain other warrant, the shares under those warrants may be exercisable using a cashless exercise feature.

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2017
FAIR VALUE MEASUREMENTS [Abstract]
Fair values by input hierarchy of items measured at fair value on a recurring basis	The following tables summarize the fair values by input hierarchy of items measured at fair value on a recurring basis on our condensed consolidated balance sheets (in thousands). Level 1 Level 2 Level 3 Total Total liabilities at fair value, as of September 30, 2017 - derivative warrant liabilities $ - $ - $ 769 $ 769 Total liabilities at fair value, as of December 31, 2016 - derivative warrant liabilities $ - $ - $ 1,527 $ 1,527
Additional assumptions used to calculate fair value	Additional assumptions that were used to calculate fair value follow. September 30, 2017 December 31, 2016 Risk-free interest rate 1.2% 0.6% -1.9% (1.2% weighted average) (1.6% weighted average) Expected volatility 67%-72% 64% (71% weighted average) (64% weighted average)
Changes in level 3 items measured at fair value	The following tables summarize the changes in Level 3 items measured at fair value on a recurring basis (in thousands): Total Level 3 Fair Value Fair Value as of Beginning of Period Total Realized and Unrealized Gains (Losses) Issuance of New Instruments Reclassify to (Deficit) Equity Conversion to Common Stock Fair Value, at End of Period (1) Nine Months Ended September 30, 2017, derivative warrant liabilities $ (1,527 ) $ 808 $ (7,917 ) $ 7,851 $ 16 $ (769 ) Nine Months Ended September 30, 2016, derivative warrant liabilities $ (678 ) $ 314 $ (2,474 ) $ - $ - $ (2,838 ) (1) Included in change in fair value of derivative warrant liabilities in our consolidated statements of operations.

DISCONTINUED OPERATIONS, Initia

DISCONTINUED OPERATIONS, Initial Distribution of Proceeds (Details) - Healthy Natural Inc [Member] - USD ($) $ in Millions	1 Months Ended	3 Months Ended	9 Months Ended
	Jul. 31, 2017	Sep. 30, 2017	Sep. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Restriction period to engage in business conducted by sold entity			5 years
Sale of assets	$ 18.3
Escrow for working capital adjustments			$ 0.2
Escrow for indemnity claims			0.6
Net carrying value of discontinued operations	$ 16.7	$ 3.5	$ 3.5
Tax provision for gain on sale of business		$ 4.3

DISCONTINUED OPERATIONS, Income

DISCONTINUED OPERATIONS, Income (Loss) from Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income (Loss) from Discontinued Operations [Abstract]
Income (loss) from discontinued operations, net of tax	$ 6,706	$ (608)	$ 6,823	$ (4,829)
Percentage of taxable income offset by net operating loss carryforwards			90.00%
Residual taxable income			10.00%
Rate of income tax on residual taxable income			20.00%
Estimated tax due			$ 300
Healthy Natural Inc [Member]
Income (Loss) from Discontinued Operations [Abstract]
Revenues	421	5,010	9,902	15,044
Cost of goods sold	(293)	(3,330)	(6,651)	(9,991)
Selling, general and administrative expenses	(19)	(396)	(462)	(1,100)
Income (loss) from discontinued operations, before income taxes	109	1,284	2,789	3,953
Income tax expense	(36)	(437)	(948)	(1,344)
Income from operations, net of tax	73	847	1,841	2,609
Gain on sale, net of $4.3 million income tax expense	8,845	0	8,845	0
Income (loss) from discontinued operations, net of tax	8,918	847	$ 10,686	2,609
Percentage of taxable income offset by net operating loss carryforwards			90.00%
Residual taxable income			10.00%
Rate of income tax on residual taxable income			20.00%
Estimated tax due			$ 300
Nutra SA [Member]
Income (Loss) from Discontinued Operations [Abstract]
Revenues	3,226	563	9,589	4,627
Cost of goods sold	(3,539)	(1,154)	(9,814)	(6,103)
Selling, general and administrative expenses	(1,541)	(509)	(2,572)	(1,891)
Goodwill impairment	0	0	0	(3,024)
Other expense	(358)	(355)	(1,066)	(1,047)
Income (loss) from discontinued operations, before income taxes	(2,212)	(1,455)	(3,863)	(7,438)
Income tax expense	0	0	0	0
Income (loss) from discontinued operations, net of tax	$ (2,212)	$ (1,455)	$ (3,863)	$ (7,438)

DISCONTINUED OPERATIONS, Major

DISCONTINUED OPERATIONS, Major Classes of Assets and Liabilities Classified as Held for Sale (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Jul. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Major Classes of Assets and Liabilities Classified as Held for Sale [Abstract]
Long term liabilities	$ 0		$ 44
Healthy Natural Inc [Member]
Major Classes of Assets and Liabilities Classified as Held for Sale [Abstract]
Accounts receivable, net		$ 871	592
Inventories		1,987	1,915
Other current assets held for sale		47	23
Property and equipment, net		871	1,019
Intangible		791	791
Other noncurrent assets		24	24
Total assets held for sale		4,591	4,364
Accounts payable		759	443
Accrued expenses		290	382
Long term liabilities			44
Total liabilities held for sale		1,049	869
Net assets sold		$ 3,542
Nutra SA [Member]
Major Classes of Assets and Liabilities Classified as Held for Sale [Abstract]
Cash and cash equivalents	54		109	$ 67	$ 104
Accounts receivable, net	781		398
Inventories	1,237		925
Other current assets held for sale	326		373
Property and equipment, net	10,464		10,889
Other noncurrent assets	1,321		1,327
Total assets held for sale	14,183		14,021
Accounts payable	2,338		2,553
Accrued expenses	8,274		5,607
Current maturities of long-term debt (nonrecourse)	7,627		6,816
Total liabilities held for sale	18,239		14,976
Property and equipment restricted	$ 2,662		$ 2,599

DISCONTINUED OPERATIONS, Cash F

DISCONTINUED OPERATIONS, Cash Flows from Discontinued Operations (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Net Cash Provided by (Used in) Discontinued Operations [Abstract]
Net cash (used in) provided by operating activities	$ 1,513	$ 3,714
Net cash provided by (used in) investing activities	16,604	(252)
Net cash provided (used) by financing activities	1,232	(551)
Effect of exchange rate changes	126	(182)
Net change in cash and cash equivalents and restricted cash	8,620	(755)
Healthy Natural Inc [Member]
Net Cash Provided by (Used in) Discontinued Operations [Abstract]
Net cash (used in) provided by operating activities	2,803	3,701
Net cash provided by (used in) investing activities	16,719	(73)
Net cash provided (used) by financing activities	(48)	0
Net cash provided (by) to continuing operations	(19,474)	(3,628)
Nutra SA [Member]
Net Cash Provided by (Used in) Discontinued Operations [Abstract]
Net cash (used in) provided by operating activities	(1,345)	(9)
Net cash provided by (used in) investing activities	(115)	(157)
Net cash provided (used) by financing activities	1,280	(551)
Net cash provided (by) to continuing operations	0	863
Effect of exchange rate changes	125	(183)
Net change in cash and cash equivalents and restricted cash	(55)	(37)
Cash and cash equivalents, beginning of period	109	104
Cash and cash equivalents, end of period	$ 54	$ 67

DISCONTINUED OPERATIONS, Other

DISCONTINUED OPERATIONS, Other Data (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Healthy Natural Inc [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capital Expenditure	$ 3	$ 22	$ 18	$ 95
Healthy Natural Inc [Member] | Cost of Goods Sold [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation	7	42	96	130
Healthy Natural Inc [Member] | Selling, General and Administrative Expenses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation	4	20	49	58
Amortization	0	204	0	659
Nutra SA [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capital Expenditure	22	1	115	157
Nutra SA [Member] | Cost of Goods Sold [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation	274	246	792	672
Nutra SA [Member] | Selling, General and Administrative Expenses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation	$ 15	$ 16	$ 46	$ 42

DISCONTINUED OPERATIONS, Compon

DISCONTINUED OPERATIONS, Components of Debt (Details) - Nutra SA [Member] $ in Thousands	6 Months Ended	9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2017USD ($)MonthlyPayment	Dec. 31, 2016USD ($)
Components of Debt [Abstract]
Capital expansion loans	$ 2,635	$ 2,635	$ 2,454
Working capital lines of credit	1,081	1,081	401
Advances on customer export orders	785	785	1,113
Special tax programs	3,014	3,014	2,767
Other	112	112	81
Total debt	7,627	7,627	$ 6,816
Brazil [Member]
Components of Debt [Abstract]
Entrance fee payments	400	400
Irgovel [Member]
Components of Debt [Abstract]
Installment payments in arrears	400	400
Tax and tax related payments in arrears	9,300	$ 9,300
Unpaid employer tax	$ 200
Maximum number of monthly payments, if unable to qualify for Tax amnesty | MonthlyPayment		60

DISCONTINUED OPERATIONS, Redeem

DISCONTINUED OPERATIONS, Redeemable Noncontrolling Interest, (Details) - Discontinued Operations [Member] - Nutra SA [Member] $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)RepresentativeInvestor	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)RepresentativeInvestor	Sep. 30, 2016USD ($)
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Redeemable noncontrolling interest in Nutra SA, beginning of period	$ (567)	$ (1,599)	$ (699)	$ 69
Investors' interest in net loss of Nutra SA	(792)	(470)	(1,359)	(2,416)
Investors' interest in other comprehensive loss of Nutra SA	(11)	(60)	38	218
Investors purchase of additional membership interest	0	200	650	200
Redeemable noncontrolling interest in Nutra SA, end of period	$ (1,370)	$ (1,929)	$ (1,370)	$ (1,929)
Investors' average interest in Nutra SA during the period	35.80%	32.50%	35.50%	32.20%
Investors' interest in Nutra SA at the end of the period	35.80%	32.70%	35.80%	32.70%
Number of representatives on management committee | Representative	3		3
Number of Investors on Management Committee | Investor	2		2
Number of representatives on management committee upon default | Representative	3		3
Number of investors on management committee upon default | Investor	2		2
EBITDA triggering default status			$ 4,000
Investors [Member]
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Drag along right, amount of initial public offering	$ 50,000		50,000
Amount paid exchange for termination of rights			$ 100

LIQUIDITY, GOING CONCERN AND 35

LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLAN (Details) - USD ($) $ in Thousands	Feb. 28, 2017	Sep. 30, 2017	Jul. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Line of Credit Facility [Abstract]
Proceeds from preference stock and warrants	$ 7,200			$ 1,747	$ 2,554
Repayment of debt	3,800
Repayment of subordinated note	$ 500
Net proceeds from issuance of common stock		$ 2,700		2,778	$ 0
HN [Member]
Line of Credit Facility [Abstract]
Cash proceeds from sale of business, net of expenses			$ 16,700
Repayment of senior debentures			6,600
Repayment of subordinated note			$ 6,000
Nutra SA [Member]
Line of Credit Facility [Abstract]
Minority partner contribution amount				$ 700		$ 1,700
Investors [Member] | Nutra SA [Member]
Noncontrolling Interest [Abstract]
Investments in variable interest entity						$ 1,100

RECENT ACCOUNTING GUIDANCE (Det

RECENT ACCOUNTING GUIDANCE (Details) - Stock Options [Member]	9 Months Ended
	Sep. 30, 2017
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Award vesting period	3 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Award vesting period	4 years

LOSS PER SHARE (EPS) (Details)

LOSS PER SHARE (EPS) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
NUMERATOR [Abstract]
Basic and diluted - loss from continuing operations	$ (4,199)	$ (942)	$ (8,387)	$ (4,975)
Dividend on preferred stock--beneficial conversion feature	0	0	(778)	(551)
Basic and diluted - adjusted loss from continuing operations	$ (4,199)	$ (942)	$ (9,165)	$ (5,526)
DENOMINATOR [Abstract]
Basic EPS - weighted average number of common shares outstanding (in shares)	11,129,781	9,397,255	10,644,372	9,281,942
Effect of dilutive securities outstanding (in shares)	0	0	0	0
Diluted EPS - weighted average number of shares outstanding (in shares)	11,129,781	9,397,255	10,644,372	9,281,942
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	629,969	340,037	473,498	350,203
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	22,824,888	10,842,006	21,306,727	10,132,045
Nonvested Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	1,301,725	1,114,747	1,236,241	1,038,019
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	2,128,180	2,000,000	3,020,739	1,611,722
Restricted Stock Unit Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	1,175,000	0	406,066	0

CONCENTRATIONS OF RISK (Details

CONCENTRATIONS OF RISK (Details)		9 Months Ended
		Sep. 30, 2017		Sep. 30, 2016
Revenue [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		100.00%		100.00%
Revenue [Member] | Customer 1 [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		17.00%		12.00%
Revenue [Member] | Customer 2 [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		15.00%		15.00%
Revenue [Member] | Customer 3 [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	[1]			12.00%
Revenue [Member] | Customer 4 [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	[1]
Revenue [Member] | Customer 5 [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	[1]
Revenue [Member] | Others [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		68.00%		61.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		100.00%		100.00%
Accounts Receivable [Member] | Customer 1 [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		31.00%		28.00%
Accounts Receivable [Member] | Customer 2 [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	[1]
Accounts Receivable [Member] | Customer 3 [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	[1]
Accounts Receivable [Member] | Customer 4 [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	[1]
Accounts Receivable [Member] | Customer 5 [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			[1]	11.00%
Accounts Receivable [Member] | Others [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		69.00%		61.00%
Purchases [Member] | Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		100.00%		100.00%
Purchases [Member] | Supplier 1 [Member] | Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			[1]	13.00%
Purchases [Member] | Supplier 2 [Member] | Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	[1]
Purchases [Member] | Supplier 3 [Member] | Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	[1]
Purchases [Member] | Supplier 4 [Member] | Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	[1]
Purchases [Member] | Supplier 5 [Member] | Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	[1]
Purchases [Member] | Others [Member] | Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		100.00%		87.00%
[1]	Less than 10%

DEBT (Details)

DEBT (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended			9 Months Ended		12 Months Ended
	Jul. 31, 2017	Feb. 28, 2017	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Total debt			$ 32			$ 32		$ 9,027
Current portion			19			19		3,063
Long-term portion			13			13		5,964
Loss on extinguishment of debt	$ 6,600		(6,610)		$ 0	(8,290)	$ 0
Senior Debentures, Net [Member] | HN [Member]
Debt Instrument [Line Items]
Carrying value of debt			600			600
Senior Debentures, Net [Member] | Maturity Due February 2019 [Member]
Debt Instrument [Line Items]
Total debt			0			0		0
Aggregate principal amount			$ 6,600			$ 6,600
Maturity date of note						Feb. 28, 2019
Effective interest rate			160.60%			160.60%
Subordinated Notes, Net [Member]
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ (1,500)
Subordinated Notes, Net [Member] | HN [Member]
Debt Instrument [Line Items]
Carrying value of debt			$ 5,300			$ 5,300
Aggregate principal amount			6,000			6,000
Subordinated Notes, Net [Member] | Maturity Due May 2019 [Member]
Debt Instrument [Line Items]
Total debt			0			0		$ 6,310
Aggregate principal amount			$ 5,900			$ 5,900
Maturity date of note						May 31, 2019
Effective interest rate			15.00%			15.00%
Variable interest rate						7.00%		11.75%
Payment of note principal				$ 200
Payment of accrued note interest				$ 300
Other [Member]
Debt Instrument [Line Items]
Total debt			$ 32			$ 32		$ 75
Senior Revolving Loan [Member]
Debt Instrument [Line Items]
Total debt			0			0		1,725
Senior Term Loan, Net [Member]
Debt Instrument [Line Items]
Total debt			$ 0			$ 0		$ 917

EQUITY, SHARE-BASED COMPENSAT40

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Summary of Equity Activity (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period		$ 7,900		$ (632)
Balance at beginning of period (in shares)				10,790,351
Issuance of common stock awards under equity incentive plans				$ 817
Dividend on preferred stock - beneficial conversion feature				0
Modification of senior debenture holder warrants				582
Modification of subordinated note holder warrants				117
Change in classification of preferred stock to equity from liability				1,545
Change in classification of warrants to equity from liability				7,851
Conversion of preferred stock into common stock				0
Proceeds from sale of common stock, net of costs				$ 2,730
Proceeds from sale of common stock, net of costs (in shares)				2,654,732
Exercise of warrant				$ 101
Other				64
Proceeds from sale of membership interests				650
Foreign currency translation				131
Net loss	$ 2,507		$ (1,550)	(1,564)	$ (9,804)
Balance at end of period	$ 12,392		$ (36)	$ 12,392	$ (36)
Balance at end of period (in shares)	16,551,350			16,551,350
Series F Preferred Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of preferred stock into common stock (in shares)	2,186	315
Series G Preferred Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of preferred stock into common stock (in shares)	689	11
Preferred Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period				$ 0
Issuance of common stock awards under equity incentive plans				0
Dividend on preferred stock - beneficial conversion feature				0
Modification of senior debenture holder warrants				0
Modification of subordinated note holder warrants				0
Change in classification of preferred stock to equity from liability				1,545
Change in classification of warrants to equity from liability				0
Conversion of preferred stock into common stock				(807)
Proceeds from sale of common stock, net of costs				0
Exercise of warrant				0
Other				0
Proceeds from sale of membership interests				0
Foreign currency translation				0
Net loss				0
Balance at end of period	$ 738			$ 738
Preferred Stock [Member] | Series F Preferred Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)				0
Issuance of common stock awards under equity incentive plans (in shares)				0
Change in classification of preferred stock to equity from liability (in shares)				3,000
Conversion of preferred stock into common stock (in shares)				(2,501)
Proceeds from sale of common stock, net of costs (in shares)				0
Exercise of warrant (in shares)				0
Other (in shares)				0
Balance at end of period (in shares)	499			499
Preferred Stock [Member] | Series G Preferred Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)				0
Issuance of common stock awards under equity incentive plans (in shares)				0
Change in classification of preferred stock to equity from liability (in shares)				2,000
Conversion of preferred stock into common stock (in shares)				(700)
Proceeds from sale of common stock, net of costs (in shares)				0
Exercise of warrant (in shares)				0
Other (in shares)				0
Balance at end of period (in shares)	1,300			1,300
Common Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period				$ 264,232
Balance at beginning of period (in shares)				10,790,351
Issuance of common stock awards under equity incentive plans				$ 817
Issuance of common stock awards under equity incentive plans (in shares)				642,839
Dividend on preferred stock - beneficial conversion feature				$ 778
Modification of senior debenture holder warrants				582
Modification of subordinated note holder warrants				117
Change in classification of preferred stock to equity from liability				$ 0
Change in classification of preferred stock to equity from liability (in shares)				0
Change in classification of warrants to equity from liability				$ 7,851
Conversion of preferred stock into common stock				$ 807
Conversion of preferred stock into common stock (in shares)	2,111,188	220,439		2,331,627
Proceeds from sale of common stock, net of costs				$ 2,730
Proceeds from sale of common stock, net of costs (in shares)				2,654,732
Exercise of warrant				$ 101
Exercise of warrant (in shares)				103,008
Other				$ 64
Other (in shares)				28,793
Proceeds from sale of membership interests				$ 0
Foreign currency translation				0
Net loss				0
Balance at end of period	$ 278,079			$ 278,079
Balance at end of period (in shares)	16,551,350			16,551,350
Accumulated Deficit [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period				$ (259,819)
Issuance of common stock awards under equity incentive plans				0
Dividend on preferred stock - beneficial conversion feature				(778)
Modification of senior debenture holder warrants				0
Modification of subordinated note holder warrants				0
Change in classification of preferred stock to equity from liability				0
Change in classification of warrants to equity from liability				0
Conversion of preferred stock into common stock				0
Proceeds from sale of common stock, net of costs				0
Exercise of warrant				0
Other				0
Proceeds from sale of membership interests				0
Foreign currency translation				0
Net loss				(205)
Balance at end of period	$ (260,802)			(260,802)
Accumulated Deficit Attributable to Non-controlling Interest in Nutra SA [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period				(699)
Issuance of common stock awards under equity incentive plans				0
Dividend on preferred stock - beneficial conversion feature				0
Modification of senior debenture holder warrants				0
Modification of subordinated note holder warrants				0
Change in classification of preferred stock to equity from liability				0
Change in classification of warrants to equity from liability				0
Conversion of preferred stock into common stock				0
Proceeds from sale of common stock, net of costs				0
Exercise of warrant				0
Other				0
Proceeds from sale of membership interests				650
Foreign currency translation				38
Net loss				(1,359)
Balance at end of period	(1,370)			(1,370)
Accumulated Other Comprehensive Loss [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period				(4,346)
Issuance of common stock awards under equity incentive plans				0
Dividend on preferred stock - beneficial conversion feature				0
Modification of senior debenture holder warrants				0
Modification of subordinated note holder warrants				0
Change in classification of preferred stock to equity from liability				0
Change in classification of warrants to equity from liability				0
Conversion of preferred stock into common stock				0
Proceeds from sale of common stock, net of costs				0
Exercise of warrant				0
Other				0
Proceeds from sale of membership interests				0
Foreign currency translation				93
Net loss				0
Balance at end of period	$ (4,253)			$ (4,253)

EQUITY, SHARE-BASED COMPENSAT41

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Warrant Activity (Details) - USD ($)	Feb. 14, 2017	Nov. 09, 2017	Aug. 31, 2017	Jun. 30, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2017	Dec. 31, 2016	Feb. 28, 2017	Jan. 31, 2017
Equity and Liability Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)		$ 2.21					$ 4.14		$ 4.14
Outstanding at end of period (in dollars per share)					$ 2.21			$ 4.14	$ 2.21	$ 4.14
Equity and Liability Warrants, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life									3 years 7 months 6 days	2 years 9 months 18 days
Increase in authorized number of shares of common stock (in shares)					50,000,000			50,000,000	50,000,000	50,000,000	50,000,000	25,000,000
Former Employee [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Common stock issued for former employee (in shares)	108,696
Cash paid in lieu of bonus	$ 100,000
Board of Directors Chairman [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Shares issued (in shares)				96,372
Transitional monthly compensation awarded							$ 8,333	$ 10,000
Transitional monthly compensation awarded in lieu of cash (in shares)							9,027	7,035
Director [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Shares issued (in shares)			35,336	345,205
Grant date fair value (in dollars per share)			$ 1.09	$ 0.90
Equity Warrants [Member]
Shares Under Warrants [Roll Forward]
Outstanding at beginning of period (in shares)		20,832,273					6,364,110		6,364,110
Issued (in shares)									0
Impact of repricing debenture purchaser warrants, Prior to repricing (in shares)									(875,000)
Impact of repricing debenture purchaser warrants, After repricing (in shares)									875,000
Impact of repricing subordinated note holder warrants, Prior to repricing (in shares)									(289,669)
Impact of repricing subordinated note holder warrants, After repricing (in shares)									289,669
Impact of anti-dilution clauses, Prior to impact (in shares)									0
Impact of anti-dilution clauses, After impact (in shares)									0
Transfer from liability to equity (in shares)									14,468,163
Exercised (in shares)									0
Forfeited, expired or cancelled (in shares)									0
Outstanding at end of period (in shares)					20,832,273			6,364,110	20,832,273	6,364,110
Exercisable at end of period (in shares)					20,832,273				20,832,273
Equity and Liability Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)		$ 2.32					$ 5.77		$ 5.77
Impact of repricing debenture purchaser warrants, Prior to repricing (in dollars per share)									5.49
Impact of repricing debenture purchaser warrants, After repricing (in dollars per share)									0.96
Impact of repricing subordinated note holder warrants, Prior to repricing (in dollars per share)									5.25
Impact of repricing subordinated note holder warrants, After repricing (in dollars per share)									0.96
Transfer from liability to equity (in dollars per share)									1.16
Outstanding at end of period (in dollars per share)					$ 2.32			$ 5.77	2.32	$ 5.77
Exercisable at end of period (in dollars per share)					$ 2.32				$ 2.32
Equity and Liability Warrants, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life									3 years 7 months 6 days	2 years 4 months 24 days
Impact of repricing debenture purchaser warrants, Prior to repricing									2 years 1 month 6 days
Impact of repricing debenture purchaser warrants, After repricing									5 years 6 months
Impact of repricing subordinated note holder warrants, Prior to repricing									3 years 3 months 18 days
Impact of repricing subordinated note holder warrants, After pricing									3 years 3 months 18 days
Transfer from liability to equity									4 years 9 months 18 days
Exercisable, weighted average remaining contractual life									3 years 7 months 6 days
Liability Warrants [Member]
Shares Under Warrants [Roll Forward]
Outstanding at beginning of period (in shares)		1,846,667					4,474,868		4,474,868
Issued (in shares)									11,783,163
Impact of repricing debenture purchaser warrants, Prior to repricing (in shares)									0
Impact of repricing debenture purchaser warrants, After repricing (in shares)									0
Impact of repricing subordinated note holder warrants, Prior to repricing (in shares)									0
Impact of repricing subordinated note holder warrants, After repricing (in shares)									0
Impact of anti-dilution clauses, Prior to impact (in shares)									(1,489,868)
Impact of anti-dilution clauses, After impact (in shares)									2,327,919
Transfer from liability to equity (in shares)									(14,468,163)
Exercised (in shares)									(781,252)
Forfeited, expired or cancelled (in shares)									0
Outstanding at end of period (in shares)					1,846,667			4,474,868	1,846,667	4,474,868
Exercisable at end of period (in shares)					1,846,667				1,846,667
Equity and Liability Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)		$ 1.06					$ 1.82		$ 1.82
Issued (in dollars per share)									0.96
Impact of anti-dilution clauses, Prior to impact (in dollars per share)									1.50
Impact of anti-dilution clauses, After impact (in dollars per share)									0.96
Transfer from liability to equity (in dollars per share)									1.16
Exercised (in dollars per share)									0.96
Outstanding at end of period (in dollars per share)					$ 1.06			$ 1.82	1.06	$ 1.82
Exercisable at end of period (in dollars per share)					$ 1.06				$ 1.06
Equity and Liability Warrants, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life									8 months 12 days	3 years 3 months 18 days
Issued									5 years
Impact of anti-dilution clauses, Prior to impact									9 months 18 days
Impact of anti-dilution clauses, After impact									9 months 18 days
Transfer from liability to equity									4 years 9 months 18 days
Exercised									0 years
Exercisable, weighted average remaining contractual life									8 months 12 days
Series F Convertible Preferred Stock [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred shares converted into common stock (in shares)					2,186	315
Number of preferred stock for conversion (in shares)					2,186	315
Carrying value of preferred stock					$ 92,000			$ 0	$ 92,000	$ 0
Series G Convertible Preferred Stock [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred shares converted into common stock (in shares)					689	11
Number of preferred stock for conversion (in shares)					689	11
Carrying value of preferred stock					$ 646,000			$ 0	$ 646,000	$ 0
Series G Convertible Preferred Stock [Member] | Subsequent Event [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred shares converted into common stock (in shares)		499
Number of preferred stock for conversion (in shares)		499
Common Stock [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred shares converted into common stock (in shares)					2,111,188	220,439			2,331,627
Number of preferred stock for conversion (in shares)					2,111,188	220,439			2,331,627
Carrying value of preferred stock to reclassified common stock					$ 700,000	$ 100,000
Stock price (in dollars per share)					$ 1.08				$ 1.08
Common Stock [Member] | Subsequent Event [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred shares converted into common stock (in shares)		332,667
Number of preferred stock for conversion (in shares)		332,667
Preferred Stock [Member] | Subsequent Event [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Carrying value of preferred stock		$ 100,000
Preferred Stock [Member] | Series F Convertible Preferred Stock [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred shares converted into common stock (in shares)									(2,501)
Number of preferred stock for conversion (in shares)									(2,501)
Preferred Stock [Member] | Series G Convertible Preferred Stock [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred shares converted into common stock (in shares)									(700)
Number of preferred stock for conversion (in shares)									(700)

EQUITY, SHARE-BASED COMPENSAT42

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS (Details)	Feb. 28, 2017USD ($)$ / sharesshares	Aug. 31, 2017shares	Jul. 31, 2017USD ($)	Jun. 30, 2017shares	Feb. 28, 2017USD ($)$ / sharesshares	Sep. 30, 2017USD ($)Installment$ / sharesshares	Jun. 30, 2017Installment$ / sharesshares	Mar. 31, 2017$ / sharesshares	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2016USD ($)	Dec. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares) | shares						22,678,940				22,678,940		10,838,978
Loss on extinguishment of debt			$ 6,600,000			$ (6,610,000)			$ 0	$ (8,290,000)	$ 0
Proceeds from issuance of debt and warrants, net of issuance costs										5,518,000	300,000
Repayment of subordinated note	$ 500,000
Repayment of debt										$ 19,728,000	$ 24,124,000
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in common shares authorized (in shares) | shares				1,700,000
Number of shares authorized (in shares) | shares						3,300,000				3,300,000
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares) | shares	2,327,919				2,327,919	781,252				781,252		1,489,868
Exercise price per warrant (in dollars per share) | $ / shares	$ 0.96				$ 0.96							$ 1.50
Warrants [Member] | Expiration February, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares) | shares	1,423,488				1,423,488
Exercise price per warrant (in dollars per share) | $ / shares	$ 0.96				$ 0.96
Series F Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock issued (in shares) | shares						499				499
Series G Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock issued (in shares) | shares	2,000				2,000	1,300				1,300
Preferred shares converted into common stock (in shares) | shares	1,897,983				1,897,983
Preferred stock conversion ratio to common stock					948.9915
Preferred stock, dividend					$ 1,000
Debt conversion amount					$ 100,000
Debt conversion, stock (in shares) | shares					180
Net proceeds from the exchange of subordinated notes					$ 1,700,000
Cash offering expenses					100,000
Proceeds allocated to derivative warrant liability					1,000,000
Warrants recorded at fair value					100,000
Loss on extinguishment of debt					(100,000)
Decrease in subordinated debt					(100,000)
Proceed recorded as preferred stock					1,200,000
Recorded dividend for preferred stock					$ 800,000
Subordinated Debt [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares) | shares	3,484,675				3,484,675
Exercise price per warrant (in dollars per share) | $ / shares	$ 0.96				$ 0.96
Loss on extinguishment of debt					$ (1,500,000)
Decrease in subordinated debt					(900,000)
Fair value of derivative warrant liabilities					2,300,000
Fair value increase in common stock					$ 100,000
Annual interest rate	7.00%				7.00%							11.75%
Repayment of debt					$ 500,000
Subordinated Debt [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price per warrant (in dollars per share) | $ / shares	$ 0.96				$ 0.96							$ 5.25
Amendment of existing warrants (in shares) | shares					289,669
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares								100,000
Granted exercise price (in dollars per share) | $ / shares								$ 0.76
Options vested (in shares) | shares		25,000
Grant date fair value (in dollars per share) | $ / shares										$ 0.56
Executive Officer and Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares							355,500
Granted exercise price (in dollars per share) | $ / shares							$ 0.85
Number of equal annual installments | Installment							4
Grant date fair value (in dollars per share) | $ / shares							$ 0.62
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares						20,000
Granted exercise price (in dollars per share) | $ / shares						$ 1.09
Number of equal annual installments | Installment						4
Grant date fair value (in dollars per share) | $ / shares						$ 0.77
Senior Secured Debt [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of debt and warrants, net of issuance costs					$ 5,500,000
Placement fees and allocation expenses					$ 500,000
Warrants exercisable term										2 years 1 month 6 days
Senior Secured Debt [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares) | shares	6,875,000				6,875,000
Exercise price per warrant (in dollars per share) | $ / shares	$ 0.96				$ 0.96
Aggregate subscription amount	$ 6,000,000				$ 6,000,000
Aggregate principal amount	$ 6,600,000				$ 6,600,000
Amendment of existing warrants (in shares) | shares					875,000
Exercise price per warrant one (in dollars per share) | $ / shares	$ 5.49				$ 5.49
Warrants exercisable term										5 years 6 months
Fair value of derivative warrant liabilities					$ 4,600,000
Fair value increase in common stock					500,000
Debt issuance cost	$ 400,000				400,000
Extinguishment of term loan					3,800,000
Repayment of subordinated note					200,000
Interest expense debt					$ 300,000

EQUITY AND SHARE-BASED COMPENSA

EQUITY AND SHARE-BASED COMPENSATION, Warrants Outstanding (Details) $ / shares in Units, $ in Millions		1 Months Ended		9 Months Ended	12 Months Ended
		Jul. 31, 2017USD ($)$ / sharesshares	Jun. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2017Warrant$ / sharesshares	Dec. 31, 2016$ / sharesshares
Summary of information related to outstanding and exercisable warrants [Abstract]
Shares under warrants, outstanding (in shares) | shares				22,678,940	10,838,978
Weighted average exercise price (in dollars per share)				$ 2.21	$ 4.14
Weighted average remaining contractual life				3 years 7 months 6 days	2 years 9 months 18 days
Shares under warrants, exercisable cashless (in shares) | shares	[1]			6,171,446
Common stock issued (in shares) | shares				2,654,732
Equity Incentive Plan 2014 [Member] | Restricted Stock Award [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Common stock issued (in shares) | shares			1,175,000
Number of trading days				65 days
Grant date fair value | $			$ 0.2
Expensed ratably term				3 years 6 months
Equity Incentive Plan 2014 [Member] | Restricted Stock Award [Member] | Vesting Price Equals or Exceeds $5.00 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Vesting percentage			10.00%
Vesting price (in dollars per share)			$ 5
Equity Incentive Plan 2014 [Member] | Restricted Stock Award [Member] | Vesting Price Equals or Exceeds $10.00 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Vesting percentage			30.00%
Vesting price (in dollars per share)			$ 10
Equity Incentive Plan 2014 [Member] | Restricted Stock Award [Member] | Vesting Price Equals or Exceeds $15.00 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Vesting percentage			60.00%
Vesting price (in dollars per share)			$ 15
Equity Warrants [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Weighted average exercise price (in dollars per share)				$ 2.32	$ 5.77
Weighted average remaining contractual life				3 years 7 months 6 days	2 years 4 months 24 days
Equity Warrants [Member] | $0.96 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)				$ 0.96
Shares under warrants, outstanding (in shares) | shares				12,947,832	0
Weighted average exercise price (in dollars per share)				$ 0.96	$ 0
Weighted average remaining contractual life				4 years 7 months 6 days	0 years
Shares under warrants, exercisable cashless (in shares) | shares	[1]			3,774,344
Equity Warrants [Member] | $2.00 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)				$ 2
Shares under warrants, outstanding (in shares) | shares				2,660,000	0
Weighted average exercise price (in dollars per share)				$ 2	$ 0
Weighted average remaining contractual life				4 years 2 months 12 days	0 years
Shares under warrants, exercisable cashless (in shares) | shares	[1]			0
Equity Warrants [Member] | $5.25 to $5.87 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, lower range limit (in dollars per share)				$ 5.25
Exercise price range, upper range limit (in dollars per share)				$ 5.87
Shares under warrants, outstanding (in shares) | shares				3,156,670	4,296,339
Weighted average exercise price (in dollars per share)				$ 5.33	$ 5.36
Weighted average remaining contractual life				2 years 2 months 12 days	2 years 8 months 12 days
Shares under warrants, exercisable cashless (in shares) | shares	[1]			359,536
Equity Warrants [Member] | $6.55 to $16.80 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, lower range limit (in dollars per share)				$ 6.55
Exercise price range, upper range limit (in dollars per share)				$ 16.80
Shares under warrants, outstanding (in shares) | shares				2,067,771	2,067,771
Weighted average exercise price (in dollars per share)				$ 6.61	$ 6.61
Weighted average remaining contractual life				1 year 6 months	2 years
Shares under warrants, exercisable cashless (in shares) | shares	[1]			190,899
Liability Warrants [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Shares under warrants, outstanding (in shares) | shares		781,522
Weighted average exercise price (in dollars per share)		$ 0.96		$ 1.06	$ 1.82
Weighted average remaining contractual life				8 months 12 days	3 years 3 months 18 days
Common stock issued (in shares) | shares		103,008
Conversion price (in dollars per share)		$ 0.98
Number of warrants | Warrant				1
Conversion loss between fair value liability and fair value of common stock | $		$ (0.1)
Liability Warrants [Member] | $0.96 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)	[2]			$ 0.96
Shares under warrants, outstanding (in shares) | shares	[2]			1,546,667	0
Weighted average exercise price (in dollars per share)	[2]			$ 0.96	$ 0
Weighted average remaining contractual life	[2]			4 months 24 days	0 years
Shares under warrants, exercisable cashless (in shares) | shares	[1],[2]			1,546,667
Liability Warrants [Member] | $1.50 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)	[3]			$ 1.50
Shares under warrants, outstanding (in shares) | shares	[3]			300,000	0
Weighted average exercise price (in dollars per share)	[3]			$ 1.60	$ 0
Weighted average remaining contractual life	[3]			2 years 10 months 24 days	0 years
Shares under warrants, exercisable cashless (in shares) | shares	[1],[3]			300,000
Liability Warrants [Member] | $1.50 to $1.60 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, lower range limit (in dollars per share)				$ 1.50
Exercise price range, upper range limit (in dollars per share)				$ 1.60
Shares under warrants, outstanding (in shares) | shares				0	1,789,868
Weighted average exercise price (in dollars per share)				$ 0	$ 1.52
Weighted average remaining contractual life				0 years	1 year 3 months 18 days
Shares under warrants, exercisable cashless (in shares) | shares	[1]			0
Liability Warrants [Member] | $2.00 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)	[4]			$ 2
Shares under warrants, outstanding (in shares) | shares	[4]			0	2,660,000
Weighted average exercise price (in dollars per share)	[4]			$ 0	$ 2
Weighted average remaining contractual life	[4]			0 years	4 years 7 months 6 days
Shares under warrants, exercisable cashless (in shares) | shares	[1],[4]			0
Liability Warrants [Member] | $5.25 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)	[4]			$ 5.25
Shares under warrants, outstanding (in shares) | shares	[4]			0	25,000
Weighted average exercise price (in dollars per share)	[4]			$ 0	$ 5.25
Weighted average remaining contractual life	[4]			0 years	3 years 7 months 6 days
Shares under warrants, exercisable cashless (in shares) | shares	[1],[4]			0
[1]	Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature. The shares listed, represent the shares holders could exercise cashless as of September 30, 2017. If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise. Should we fail to maintain a registration statement for the resale of shares under certain other warrant, the shares under those warrants may be exercisable using a cashless exercise feature.
[2]	Includes one warrant which contains full ratchet anti-dilution provisions and is classified as derivative warrant liabilities in our balance sheet. Under the anti-dilution clause contained in this warrant, in the event of equity issuances (i.e. issuances of our common stock, certain awards of stock options to employees, and issuances of warrants and/or other convertible instruments) at prices below the exercise price of this warrant, we are required to lower the exercise price on this warrant and increase the number of shares underlying this warrant.
[3]	Includes a warrant to purchase of 300,000 shares of our common stock which contains a most favored nations anti-dilution provision. Under that provision, in the event we issue warrants and/or other convertible instruments with anti-dilution provisions with respect to the exercise price of the warrant or the conversion price of the convertible instrument, we will be required to provide the same anti-dilution provision in this warrant and may be required to lower the exercise price on this warrant and/or increase the number of shares underlying this warrant.
[4]	The warrants were classified as derivative warrant liabilities in our balance sheets due to the Share Sequencing as of December 31, 2016, and were reclassified to equity (deficit) effective March 31, 2017.

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying value of debt	$ 32	$ 9,027
Derivative Warrant Liabilities [Member] | Recurring [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	$ 769	$ 1,527
Additional assumptions used to calculate fair value [Abstract]
Risk-free interest rate	1.20%
Expected volatility		64.00%
Derivative Warrant Liabilities [Member] | Recurring [Member] | Minimum [Member]
Additional assumptions used to calculate fair value [Abstract]
Risk-free interest rate		0.60%
Expected volatility	67.00%
Derivative Warrant Liabilities [Member] | Recurring [Member] | Maximum [Member]
Additional assumptions used to calculate fair value [Abstract]
Risk-free interest rate		1.90%
Expected volatility	72.00%
Derivative Warrant Liabilities [Member] | Recurring [Member] | Weighted Average [Member]
Additional assumptions used to calculate fair value [Abstract]
Risk-free interest rate	1.20%	1.60%
Expected volatility	71.00%	64.00%
Derivative Warrant Liabilities [Member] | Level 1 [Member] | Recurring [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	$ 0	$ 0
Derivative Warrant Liabilities [Member] | Level 2 [Member] | Recurring [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	0	0
Derivative Warrant Liabilities [Member] | Level 3 [Member] | Recurring [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	$ 769	$ 1,527

FAIR VALUE MEASUREMENTS, Unobse

FAIR VALUE MEASUREMENTS, Unobservable Input Reconciliation (Details) - Recurring [Member] - Derivative Warrant Liabilities [Member] - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2017	Sep. 30, 2016
Changes in level 3 items measured at fair value on a recurring basis [Roll Forward]
Fair Value as of Beginning of Period		$ (1,527)	$ (678)
Total Realized and Unrealized Gains (Losses)	[1]	808	314
Issuance of New Instruments		(7,917)	(2,474)
Reclassify to (Deficit) Equity		7,851	0
Conversion to Common Stock		16	0
Fair Value, at End of Period		$ (769)	$ (2,838)
[1]	Included in change in fair value of derivative warrant liabilities in our unaudited condensed consolidated statements of operations.

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - 9 months ended Sep. 30, 2017 - Irgovel [Member] BRL in Millions, $ in Millions	BRL	USD ($)
Loss Contingencies [Line Items]
Damages sought by plaintiff		$ 1.1
Contingent liability		$ 0.3
Minimum [Member]
Irgovel - Events of Default [Abstract]
EBITDA triggering default status | BRL	BRL 4

INCOME TAXES (Details)

INCOME TAXES (Details) $ in Millions	9 Months Ended
	Sep. 30, 2017USD ($)
INCOME TAXES [Abstract]
Percentage of taxable income offset by net operating loss carryforwards	90.00%
Residual taxable income	10.00%
Income Tax Rate On Residual Taxable Income	20.00%
Estimated tax due	$ 0.3

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)Nomineeshares	Sep. 30, 2016USD ($)
Related Party Transaction [Line Items]
Percentage of outstanding debt retained by related party			16.00%
Interest paid			$ 729	$ 780
Sale of common stock (in shares) | shares			2,654,732
Halpern [Member]
Related Party Transaction [Line Items]
Percentage of outstanding debt retained by related party			43.00%
Halpern [Member] | Subordinated Notes [Member]
Related Party Transaction [Line Items]
Interest paid	$ 100	$ 100	$ 200	$ 200
Continental Grain Company [Member]
Related Party Transaction [Line Items]
Number of nominee for the Board of Directors related party can designate | Nominee			1

FAILURE TO COMPLY WITH NASDAQ49

FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Aug. 18, 2016
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS [Abstract]
Nasdaq minimum stockholders' equity listing requirement					$ 2,500
Stockholders' equity (deficit)	$ 12,392	$ 7,900	$ (632)	$ (36)
Nasdaq grant of extension period to regain compliance under minimum stockholders' equity requirement	180 days
Nasdaq minimum bid price requirement (in dollars per share)	$ 1
Number of consecutive business days at minimum bid price to regain compliance	10 days
Number of consecutive business days under minimum bid requirement, out of compliance	30 days